CN101437563B - atomizer - Google Patents
atomizer Download PDFInfo
- Publication number
- CN101437563B CN101437563B CN200780016624.0A CN200780016624A CN101437563B CN 101437563 B CN101437563 B CN 101437563B CN 200780016624 A CN200780016624 A CN 200780016624A CN 101437563 B CN101437563 B CN 101437563B
- Authority
- CN
- China
- Prior art keywords
- nebulizer
- amino
- container
- storage
- delivery
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 claims abstract description 28
- 238000009472 formulation Methods 0.000 claims abstract description 25
- 239000006199 nebulizer Substances 0.000 claims description 168
- 238000003860 storage Methods 0.000 claims description 133
- 238000002360 preparation method Methods 0.000 claims description 51
- 238000004146 energy storage Methods 0.000 claims description 27
- 230000005540 biological transmission Effects 0.000 claims description 26
- 238000010276 construction Methods 0.000 claims description 4
- 229920003023 plastic Polymers 0.000 claims description 4
- 239000004033 plastic Substances 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 2
- 239000011888 foil Substances 0.000 claims description 2
- 229910052751 metal Inorganic materials 0.000 claims description 2
- 239000002184 metal Substances 0.000 claims description 2
- 238000000889 atomisation Methods 0.000 abstract description 35
- 239000000843 powder Substances 0.000 abstract description 12
- 238000000034 method Methods 0.000 abstract description 10
- 238000007599 discharging Methods 0.000 abstract description 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 113
- 239000002585 base Substances 0.000 description 108
- -1 EGFR-inhibitor Substances 0.000 description 90
- 229910052760 oxygen Inorganic materials 0.000 description 67
- 239000001301 oxygen Substances 0.000 description 67
- 125000001207 fluorophenyl group Chemical group 0.000 description 61
- 230000033001 locomotion Effects 0.000 description 54
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 39
- 150000003839 salts Chemical class 0.000 description 29
- 238000005187 foaming Methods 0.000 description 19
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 16
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 16
- 210000000515 tooth Anatomy 0.000 description 15
- 150000001875 compounds Chemical class 0.000 description 14
- 230000007246 mechanism Effects 0.000 description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 13
- XQJMXPAEFMWDOZ-UHFFFAOYSA-N 3exo-benzoyloxy-tropane Natural products CN1C(C2)CCC1CC2OC(=O)C1=CC=CC=C1 XQJMXPAEFMWDOZ-UHFFFAOYSA-N 0.000 description 12
- QQXLDOJGLXJCSE-UHFFFAOYSA-N N-methylnortropinone Natural products C1C(=O)CC2CCC1N2C QQXLDOJGLXJCSE-UHFFFAOYSA-N 0.000 description 12
- 229910019142 PO4 Inorganic materials 0.000 description 12
- QIZDQFOVGFDBKW-DHBOJHSNSA-N Pseudotropine Natural products OC1C[C@@H]2[N+](C)[C@H](C1)CC2 QIZDQFOVGFDBKW-DHBOJHSNSA-N 0.000 description 12
- 239000010452 phosphate Substances 0.000 description 12
- FIMXSEMBHGTNKT-UHFFFAOYSA-N Scopine Natural products CN1C2CC(O)CC1C1C2O1 FIMXSEMBHGTNKT-UHFFFAOYSA-N 0.000 description 11
- 230000003213 activating effect Effects 0.000 description 11
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 10
- 239000012530 fluid Substances 0.000 description 10
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 10
- 239000000463 material Substances 0.000 description 9
- 238000007789 sealing Methods 0.000 description 9
- 239000012453 solvate Substances 0.000 description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 8
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 8
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 8
- 239000005557 antagonist Substances 0.000 description 8
- 238000010586 diagram Methods 0.000 description 8
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 8
- 229940095064 tartrate Drugs 0.000 description 8
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 7
- 241001597008 Nomeidae Species 0.000 description 7
- 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 description 7
- 229940121647 egfr inhibitor Drugs 0.000 description 7
- 229960003210 hyoscyamine Drugs 0.000 description 7
- 229930005342 hyoscyamine Natural products 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical group [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 description 7
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 description 7
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 6
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 6
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 6
- 229910002651 NO3 Inorganic materials 0.000 description 6
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 6
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 6
- 239000003246 corticosteroid Substances 0.000 description 6
- 239000003595 mist Substances 0.000 description 6
- 150000003891 oxalate salts Chemical class 0.000 description 6
- 238000005086 pumping Methods 0.000 description 6
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 6
- 229950004288 tosilate Drugs 0.000 description 6
- 238000012546 transfer Methods 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 5
- 150000001450 anions Chemical class 0.000 description 5
- 229940006460 bromide ion Drugs 0.000 description 5
- 150000003842 bromide salts Chemical group 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 238000007906 compression Methods 0.000 description 5
- 230000006835 compression Effects 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 230000029058 respiratory gaseous exchange Effects 0.000 description 5
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 230000001078 anti-cholinergic effect Effects 0.000 description 4
- 230000000903 blocking effect Effects 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000007789 gas Substances 0.000 description 4
- UTEFBSAVJNEPTR-RGEXLXHISA-N loprazolam Chemical compound C1CN(C)CCN1\C=C/1C(=O)N2C3=CC=C([N+]([O-])=O)C=C3C(C=3C(=CC=CC=3)Cl)=NCC2=N\1 UTEFBSAVJNEPTR-RGEXLXHISA-N 0.000 description 4
- 229960003019 loprazolam Drugs 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 4
- ZISSAWUMDACLOM-UHFFFAOYSA-N triptane Chemical compound CC(C)C(C)(C)C ZISSAWUMDACLOM-UHFFFAOYSA-N 0.000 description 4
- PZDAAZQDQJGXSW-UHFFFAOYSA-N 1-fluoro-4-(4-fluorophenyl)benzene Chemical group C1=CC(F)=CC=C1C1=CC=C(F)C=C1 PZDAAZQDQJGXSW-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 239000003513 alkali Substances 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- XMBWDFGMSWQBCA-UHFFFAOYSA-M iodide Chemical compound [I-] XMBWDFGMSWQBCA-UHFFFAOYSA-M 0.000 description 3
- 229940006461 iodide ion Drugs 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate group Chemical class CS(=O)(=O)[O-] AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- 238000003825 pressing Methods 0.000 description 3
- IAGDDPYFLFGQCX-UHFFFAOYSA-N 1-fluoro-9h-fluorene Chemical class C12=CC=CC=C2CC2=C1C=CC=C2F IAGDDPYFLFGQCX-UHFFFAOYSA-N 0.000 description 2
- SMNDYUVBFMFKNZ-UHFFFAOYSA-N 2-furoic acid Chemical compound OC(=O)C1=CC=CO1 SMNDYUVBFMFKNZ-UHFFFAOYSA-N 0.000 description 2
- ULMFXAMQUGLVGA-LJQANCHMSA-N 3-[[2-methoxy-4-[(2-methylphenyl)sulfonylcarbamoyl]phenyl]methyl]-1-methyl-n-[(2r)-4,4,4-trifluoro-2-methylbutyl]indole-5-carboxamide Chemical compound C=1C=C(CC=2C3=CC(=CC=C3N(C)C=2)C(=O)NC[C@H](C)CC(F)(F)F)C(OC)=CC=1C(=O)NS(=O)(=O)C1=CC=CC=C1C ULMFXAMQUGLVGA-LJQANCHMSA-N 0.000 description 2
- CVDXFPBVOIERBH-JWQCQUIFSA-N 4-[(4ar,10bs)-9-ethoxy-8-methoxy-2-methyl-3,4,4a,10b-tetrahydro-1h-benzo[c][1,6]naphthyridin-6-yl]-n,n-di(propan-2-yl)benzamide Chemical compound N([C@@H]1CCN(C)C[C@@H]1C=1C=C(C(=CC=11)OC)OCC)=C1C1=CC=C(C(=O)N(C(C)C)C(C)C)C=C1 CVDXFPBVOIERBH-JWQCQUIFSA-N 0.000 description 2
- PYUGFOWNYMLROI-KPKJPENVSA-N 8-[(e)-2-[4-[4-(4-fluorophenyl)butoxy]phenyl]ethenyl]-2-(2h-tetrazol-5-yl)chromen-4-one Chemical compound C1=CC(F)=CC=C1CCCCOC(C=C1)=CC=C1\C=C\C1=CC=CC2=C1OC(C=1NN=NN=1)=CC2=O PYUGFOWNYMLROI-KPKJPENVSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 description 2
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 2
- DHCOPPHTVOXDKU-UHFFFAOYSA-N Tofimilast Chemical compound C1CN2C(C=3SC=CC=3)=NN=C2C2=C1C(CC)=NN2C1CCCC1 DHCOPPHTVOXDKU-UHFFFAOYSA-N 0.000 description 2
- ANGKOCUUWGHLCE-HKUYNNGSSA-N [(3s)-1,1-dimethylpyrrolidin-1-ium-3-yl] (2r)-2-cyclopentyl-2-hydroxy-2-phenylacetate Chemical compound C1[N+](C)(C)CC[C@@H]1OC(=O)[C@](O)(C=1C=CC=CC=1)C1CCCC1 ANGKOCUUWGHLCE-HKUYNNGSSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 239000000739 antihistaminic agent Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-M benzoate Chemical compound [O-]C(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-M 0.000 description 2
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 2
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 2
- 239000000812 cholinergic antagonist Substances 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 239000003136 dopamine receptor stimulating agent Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 229960002848 formoterol Drugs 0.000 description 2
- BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 description 2
- 239000001530 fumaric acid Substances 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 2
- OEXHQOGQTVQTAT-JRNQLAHRSA-N ipratropium Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 OEXHQOGQTVQTAT-JRNQLAHRSA-N 0.000 description 2
- 229960003088 loratadine Drugs 0.000 description 2
- JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 description 2
- LMOINURANNBYCM-UHFFFAOYSA-N metaproterenol Chemical compound CC(C)NCC(O)C1=CC(O)=CC(O)=C1 LMOINURANNBYCM-UHFFFAOYSA-N 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- DPHDSIQHVGSITN-UHFFFAOYSA-N n-(3,5-dichloropyridin-4-yl)-2-[1-[(4-fluorophenyl)methyl]-5-hydroxyindol-3-yl]-2-oxoacetamide Chemical compound C1=C(C(=O)C(=O)NC=2C(=CN=CC=2Cl)Cl)C2=CC(O)=CC=C2N1CC1=CC=C(F)C=C1 DPHDSIQHVGSITN-UHFFFAOYSA-N 0.000 description 2
- HHRNQOGXBRYCHF-UHFFFAOYSA-N n-[2-hydroxy-5-[1-hydroxy-2-(propan-2-ylamino)ethyl]phenyl]methanesulfonamide Chemical compound CC(C)NCC(O)C1=CC=C(O)C(NS(C)(=O)=O)=C1 HHRNQOGXBRYCHF-UHFFFAOYSA-N 0.000 description 2
- 229960002657 orciprenaline Drugs 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 229950010765 pivalate Drugs 0.000 description 2
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 2
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 2
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 229950010289 soterenol Drugs 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- LERNTVKEWCAPOY-DZZGSBJMSA-N tiotropium Chemical compound O([C@H]1C[C@@H]2[N+]([C@H](C1)[C@@H]1[C@H]2O1)(C)C)C(=O)C(O)(C=1SC=CC=1)C1=CC=CS1 LERNTVKEWCAPOY-DZZGSBJMSA-N 0.000 description 2
- OOGJQPCLVADCPB-HXUWFJFHSA-N tolterodine Chemical compound C1([C@@H](CCN(C(C)C)C(C)C)C=2C(=CC=C(C)C=2)O)=CC=CC=C1 OOGJQPCLVADCPB-HXUWFJFHSA-N 0.000 description 2
- OYYDSUSKLWTMMQ-JKHIJQBDSA-N trospium Chemical compound [N+]12([C@@H]3CC[C@H]2C[C@H](C3)OC(=O)C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CCCC1 OYYDSUSKLWTMMQ-JKHIJQBDSA-N 0.000 description 2
- 229920002554 vinyl polymer Polymers 0.000 description 2
- XJBCFFLVLOPYBV-UHFFFAOYSA-N zinterol Chemical compound C=1C=C(O)C(NS(C)(=O)=O)=CC=1C(O)CNC(C)(C)CC1=CC=CC=C1 XJBCFFLVLOPYBV-UHFFFAOYSA-N 0.000 description 2
- 229950004209 zinterol Drugs 0.000 description 2
- XJSMBWUHHJFJFV-VTIMJTGVSA-N α-dihydroergocryptine Chemical compound C([C@H]1N(C)C2)C([C]34)=CN=C4C=CC=C3[C@H]1C[C@H]2C(=O)N[C@@]1(C(C)C)C(=O)N2[C@@H](CC(C)C)C(=O)N3CCC[C@H]3[C@]2(O)O1 XJSMBWUHHJFJFV-VTIMJTGVSA-N 0.000 description 2
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 1
- XWTYSIMOBUGWOL-UHFFFAOYSA-N (+-)-Terbutaline Chemical compound CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1 XWTYSIMOBUGWOL-UHFFFAOYSA-N 0.000 description 1
- NDAUXUAQIAJITI-LBPRGKRZSA-N (R)-salbutamol Chemical compound CC(C)(C)NC[C@H](O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-LBPRGKRZSA-N 0.000 description 1
- YVAIFZYQODGYQY-UHFFFAOYSA-N 2,3-dihydro-1,3-benzothiazole 1-oxide Chemical class C1=CC=C2S(=O)CNC2=C1 YVAIFZYQODGYQY-UHFFFAOYSA-N 0.000 description 1
- SPCKHVPPRJWQRZ-UHFFFAOYSA-N 2-benzhydryloxy-n,n-dimethylethanamine;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 SPCKHVPPRJWQRZ-UHFFFAOYSA-N 0.000 description 1
- KVVDRQDTODKIJD-UHFFFAOYSA-N 2-cyclopropylacetic acid Chemical compound OC(=O)CC1CC1 KVVDRQDTODKIJD-UHFFFAOYSA-N 0.000 description 1
- XBUSQTCUZRYVMT-UHFFFAOYSA-N 2-hydroxy-5-[1-hydroxy-2-[2-[4-[(2-hydroxy-2-phenylethyl)amino]phenyl]ethylamino]ethyl]benzaldehyde Chemical compound C=1C=C(O)C(C=O)=CC=1C(O)CNCCC(C=C1)=CC=C1NCC(O)C1=CC=CC=C1 XBUSQTCUZRYVMT-UHFFFAOYSA-N 0.000 description 1
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 1
- DDYUBCCTNHWSQM-UHFFFAOYSA-N 3-(3-cyclopentyloxy-4-methoxyphenyl)-3-(1,3-dioxoisoindol-2-yl)propanamide Chemical compound COC1=CC=C(C(CC(N)=O)N2C(C3=CC=CC=C3C2=O)=O)C=C1OC1CCCC1 DDYUBCCTNHWSQM-UHFFFAOYSA-N 0.000 description 1
- LIXBJWRFCNRAPA-NSHDSACASA-N 4-[(1r)-2-(tert-butylamino)-1-hydroxyethyl]-3-chlorophenol Chemical compound CC(C)(C)NC[C@H](O)C1=CC=C(O)C=C1Cl LIXBJWRFCNRAPA-NSHDSACASA-N 0.000 description 1
- UTUUPXBCDMQYRR-HSZRJFAPSA-N 4-[(2r)-2-(3-cyclopentyloxy-4-methoxyphenyl)-2-phenylethyl]pyridine Chemical compound COC1=CC=C([C@H](CC=2C=CN=CC=2)C=2C=CC=CC=2)C=C1OC1CCCC1 UTUUPXBCDMQYRR-HSZRJFAPSA-N 0.000 description 1
- LIXBJWRFCNRAPA-UHFFFAOYSA-N 4-[2-(tert-butylamino)-1-hydroxyethyl]-3-chlorophenol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C=C1Cl LIXBJWRFCNRAPA-UHFFFAOYSA-N 0.000 description 1
- MNJNSRQVLNIPFN-UHFFFAOYSA-N 4-[2-[[4-(benzimidazol-1-yl)-2-methylbutan-2-yl]amino]-1-hydroxyethyl]-2-[(4-methoxyphenyl)methylamino]phenol Chemical compound C1=CC(OC)=CC=C1CNC1=CC(C(O)CNC(C)(C)CCN2C3=CC=CC=C3N=C2)=CC=C1O MNJNSRQVLNIPFN-UHFFFAOYSA-N 0.000 description 1
- XRYJULCDUUATMC-CYBMUJFWSA-N 4-[4-[[(1r)-1-phenylethyl]amino]-7h-pyrrolo[2,3-d]pyrimidin-6-yl]phenol Chemical compound N([C@H](C)C=1C=CC=CC=1)C(C=1C=2)=NC=NC=1NC=2C1=CC=C(O)C=C1 XRYJULCDUUATMC-CYBMUJFWSA-N 0.000 description 1
- FBXGQDUVJBKEAJ-UHFFFAOYSA-N 4h-oxazin-3-one Chemical compound O=C1CC=CON1 FBXGQDUVJBKEAJ-UHFFFAOYSA-N 0.000 description 1
- LSLYOANBFKQKPT-DIFFPNOSSA-N 5-[(1r)-1-hydroxy-2-[[(2r)-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]benzene-1,3-diol Chemical compound C([C@@H](C)NC[C@H](O)C=1C=C(O)C=C(O)C=1)C1=CC=C(O)C=C1 LSLYOANBFKQKPT-DIFFPNOSSA-N 0.000 description 1
- DHSSDEDRBUKTQY-UHFFFAOYSA-N 6-prop-2-enyl-4,5,7,8-tetrahydrothiazolo[4,5-d]azepin-2-amine Chemical compound C1CN(CC=C)CCC2=C1N=C(N)S2 DHSSDEDRBUKTQY-UHFFFAOYSA-N 0.000 description 1
- MBUVEWMHONZEQD-UHFFFAOYSA-N Azeptin Chemical compound C1CN(C)CCCC1N1C(=O)C2=CC=CC=C2C(CC=2C=CC(Cl)=CC=2)=N1 MBUVEWMHONZEQD-UHFFFAOYSA-N 0.000 description 1
- KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 description 1
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 1
- QGBIFMJAQARMNQ-QISPFCDLSA-N C1([C@@H](F)C2)=CC(=O)CC[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3O[C@@H](CCC)O[C@@]3(SC)[C@@]2(C)C[C@@H]1O Chemical compound C1([C@@H](F)C2)=CC(=O)CC[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3O[C@@H](CCC)O[C@@]3(SC)[C@@]2(C)C[C@@H]1O QGBIFMJAQARMNQ-QISPFCDLSA-N 0.000 description 1
- 229940127597 CGRP antagonist Drugs 0.000 description 1
- KORNTPPJEAJQIU-KJXAQDMKSA-N Cabaser Chemical compound C1=CC([C@H]2C[C@H](CN(CC=C)[C@@H]2C2)C(=O)N(CCCN(C)C)C(=O)NCC)=C3C2=CNC3=C1 KORNTPPJEAJQIU-KJXAQDMKSA-N 0.000 description 1
- ZKLPARSLTMPFCP-UHFFFAOYSA-N Cetirizine Chemical compound C1CN(CCOCC(=O)O)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-UHFFFAOYSA-N 0.000 description 1
- LUKZNWIVRBCLON-GXOBDPJESA-N Ciclesonide Chemical compound C1([C@H]2O[C@@]3([C@H](O2)C[C@@H]2[C@@]3(C[C@H](O)[C@@H]3[C@@]4(C)C=CC(=O)C=C4CC[C@H]32)C)C(=O)COC(=O)C(C)C)CCCCC1 LUKZNWIVRBCLON-GXOBDPJESA-N 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 1
- HUYWAWARQUIQLE-UHFFFAOYSA-N Isoetharine Chemical compound CC(C)NC(CC)C(O)C1=CC=C(O)C(O)=C1 HUYWAWARQUIQLE-UHFFFAOYSA-N 0.000 description 1
- PWWVAXIEGOYWEE-UHFFFAOYSA-N Isophenergan Chemical compound C1=CC=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 PWWVAXIEGOYWEE-UHFFFAOYSA-N 0.000 description 1
- ZCVMWBYGMWKGHF-UHFFFAOYSA-N Ketotifene Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2CC(=O)C2=C1C=CS2 ZCVMWBYGMWKGHF-UHFFFAOYSA-N 0.000 description 1
- OCJYIGYOJCODJL-UHFFFAOYSA-N Meclizine Chemical compound CC1=CC=CC(CN2CCN(CC2)C(C=2C=CC=CC=2)C=2C=CC(Cl)=CC=2)=C1 OCJYIGYOJCODJL-UHFFFAOYSA-N 0.000 description 1
- PVLJETXTTWAYEW-UHFFFAOYSA-N Mizolastine Chemical compound N=1C=CC(=O)NC=1N(C)C(CC1)CCN1C1=NC2=CC=CC=C2N1CC1=CC=C(F)C=C1 PVLJETXTTWAYEW-UHFFFAOYSA-N 0.000 description 1
- UCHDWCPVSPXUMX-TZIWLTJVSA-N Montelukast Chemical compound CC(C)(O)C1=CC=CC=C1CC[C@H](C=1C=C(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)C=CC=1)SCC1(CC(O)=O)CC1 UCHDWCPVSPXUMX-TZIWLTJVSA-N 0.000 description 1
- IJHNSHDBIRRJRN-UHFFFAOYSA-N N,N-dimethyl-3-phenyl-3-(2-pyridinyl)-1-propanamine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=CC=C1 IJHNSHDBIRRJRN-UHFFFAOYSA-N 0.000 description 1
- 125000003047 N-acetyl group Chemical group 0.000 description 1
- JAUOIFJMECXRGI-UHFFFAOYSA-N Neoclaritin Chemical compound C=1C(Cl)=CC=C2C=1CCC1=CC=CN=C1C2=C1CCNCC1 JAUOIFJMECXRGI-UHFFFAOYSA-N 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- VQDBNKDJNJQRDG-UHFFFAOYSA-N Pirbuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=N1 VQDBNKDJNJQRDG-UHFFFAOYSA-N 0.000 description 1
- BPZSYCZIITTYBL-YJYMSZOUSA-N R-Formoterol Chemical compound C1=CC(OC)=CC=C1C[C@@H](C)NC[C@H](O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-YJYMSZOUSA-N 0.000 description 1
- BKRGVLQUQGGVSM-KBXCAEBGSA-N Revanil Chemical compound C1=CC(C=2[C@H](N(C)C[C@H](C=2)NC(=O)N(CC)CC)C2)=C3C2=CNC3=C1 BKRGVLQUQGGVSM-KBXCAEBGSA-N 0.000 description 1
- RUOGJYKOQBFJIG-UHFFFAOYSA-N SCH-351591 Chemical compound C12=CC=C(C(F)(F)F)N=C2C(OC)=CC=C1C(=O)NC1=C(Cl)C=[N+]([O-])C=C1Cl RUOGJYKOQBFJIG-UHFFFAOYSA-N 0.000 description 1
- VPMWDFRZSIMDKW-YJYMSZOUSA-N Salmefamol Chemical compound C1=CC(OC)=CC=C1C[C@@H](C)NC[C@H](O)C1=CC=C(O)C(CO)=C1 VPMWDFRZSIMDKW-YJYMSZOUSA-N 0.000 description 1
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- JOAHPSVPXZTVEP-YXJHDRRASA-N Terguride Chemical compound C1=CC([C@H]2C[C@@H](CN(C)[C@@H]2C2)NC(=O)N(CC)CC)=C3C2=CNC3=C1 JOAHPSVPXZTVEP-YXJHDRRASA-N 0.000 description 1
- YEEZWCHGZNKEEK-UHFFFAOYSA-N Zafirlukast Chemical compound COC1=CC(C(=O)NS(=O)(=O)C=2C(=CC=CC=2)C)=CC=C1CC(C1=C2)=CN(C)C1=CC=C2NC(=O)OC1CCCC1 YEEZWCHGZNKEEK-UHFFFAOYSA-N 0.000 description 1
- HOAKOHHSHOCDLI-TUFAYURCSA-N [(8s,9s,10r,11s,13s,14s,17r)-11-hydroxy-10,13-dimethyl-3-oxo-17-(2-sulfanylacetyl)-2,6,7,8,9,11,12,14,15,16-decahydro-1h-cyclopenta[a]phenanthren-17-yl] butanoate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)CS)(OC(=O)CCC)[C@@]1(C)C[C@@H]2O HOAKOHHSHOCDLI-TUFAYURCSA-N 0.000 description 1
- YPFLFUJKZDAXRA-UHFFFAOYSA-N [3-(carbamoylamino)-2-(2,4-dichlorobenzoyl)-1-benzofuran-6-yl] methanesulfonate Chemical compound O1C2=CC(OS(=O)(=O)C)=CC=C2C(NC(N)=O)=C1C(=O)C1=CC=C(Cl)C=C1Cl YPFLFUJKZDAXRA-UHFFFAOYSA-N 0.000 description 1
- WKHOPHIMYDJVSA-UHFFFAOYSA-N [3-[2-(tert-butylamino)-1-hydroxyethyl]-5-(2-methylpropanoyloxy)phenyl] 2-methylpropanoate Chemical compound CC(C)C(=O)OC1=CC(OC(=O)C(C)C)=CC(C(O)CNC(C)(C)C)=C1 WKHOPHIMYDJVSA-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000000808 adrenergic beta-agonist Substances 0.000 description 1
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 1
- 229960001692 arformoterol Drugs 0.000 description 1
- GVTLDPJNRVMCAL-UHFFFAOYSA-N arofylline Chemical compound C1=2N=CNC=2C(=O)N(CCC)C(=O)N1C1=CC=C(Cl)C=C1 GVTLDPJNRVMCAL-UHFFFAOYSA-N 0.000 description 1
- 229950009746 arofylline Drugs 0.000 description 1
- 229960004574 azelastine Drugs 0.000 description 1
- 229960003060 bambuterol Drugs 0.000 description 1
- ANZXOIAKUNOVQU-UHFFFAOYSA-N bambuterol Chemical compound CN(C)C(=O)OC1=CC(OC(=O)N(C)C)=CC(C(O)CNC(C)(C)C)=C1 ANZXOIAKUNOVQU-UHFFFAOYSA-N 0.000 description 1
- 229960002526 bamipine Drugs 0.000 description 1
- VZSXTYKGYWISGQ-UHFFFAOYSA-N bamipine Chemical compound C1CN(C)CCC1N(C=1C=CC=CC=1)CC1=CC=CC=C1 VZSXTYKGYWISGQ-UHFFFAOYSA-N 0.000 description 1
- 229960004495 beclometasone Drugs 0.000 description 1
- 229960002537 betamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 1
- 230000003454 betamimetic effect Effects 0.000 description 1
- 230000002457 bidirectional effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960004620 bitolterol Drugs 0.000 description 1
- FZGVEKPRDOIXJY-UHFFFAOYSA-N bitolterol Chemical compound C1=CC(C)=CC=C1C(=O)OC1=CC=C(C(O)CNC(C)(C)C)C=C1OC(=O)C1=CC=C(C)C=C1 FZGVEKPRDOIXJY-UHFFFAOYSA-N 0.000 description 1
- 229960002802 bromocriptine Drugs 0.000 description 1
- OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 description 1
- JBRBWHCVRGURBA-UHFFFAOYSA-N broxaterol Chemical compound CC(C)(C)NCC(O)C1=CC(Br)=NO1 JBRBWHCVRGURBA-UHFFFAOYSA-N 0.000 description 1
- 229950008847 broxaterol Drugs 0.000 description 1
- 229960004436 budesonide Drugs 0.000 description 1
- 229950001167 butixocort Drugs 0.000 description 1
- 229960004596 cabergoline Drugs 0.000 description 1
- 239000003735 calcitonin gene related peptide receptor antagonist Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 229960001386 carbuterol Drugs 0.000 description 1
- KEMXXQOFIRIICG-UHFFFAOYSA-N carbuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(NC(N)=O)=C1 KEMXXQOFIRIICG-UHFFFAOYSA-N 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 229960001803 cetirizine Drugs 0.000 description 1
- 229960005395 cetuximab Drugs 0.000 description 1
- CFBUZOUXXHZCFB-OYOVHJISSA-N chembl511115 Chemical compound COC1=CC=C([C@@]2(CC[C@H](CC2)C(O)=O)C#N)C=C1OC1CCCC1 CFBUZOUXXHZCFB-OYOVHJISSA-N 0.000 description 1
- 150000003841 chloride salts Chemical class 0.000 description 1
- 229960003686 chlorphenoxamine Drugs 0.000 description 1
- KKHPNPMTPORSQE-UHFFFAOYSA-N chlorphenoxamine Chemical compound C=1C=C(Cl)C=CC=1C(C)(OCCN(C)C)C1=CC=CC=C1 KKHPNPMTPORSQE-UHFFFAOYSA-N 0.000 description 1
- 229960003728 ciclesonide Drugs 0.000 description 1
- 229950001653 cilomilast Drugs 0.000 description 1
- 229960002881 clemastine Drugs 0.000 description 1
- YNNUSGIPVFPVBX-NHCUHLMSSA-N clemastine Chemical compound CN1CCC[C@@H]1CCO[C@@](C)(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 YNNUSGIPVFPVBX-NHCUHLMSSA-N 0.000 description 1
- 229960001117 clenbuterol Drugs 0.000 description 1
- STJMRWALKKWQGH-UHFFFAOYSA-N clenbuterol Chemical compound CC(C)(C)NCC(O)C1=CC(Cl)=C(N)C(Cl)=C1 STJMRWALKKWQGH-UHFFFAOYSA-N 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 229960001145 deflazacort Drugs 0.000 description 1
- FBHSPRKOSMHSIF-GRMWVWQJSA-N deflazacort Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(C)=N[C@@]3(C(=O)COC(=O)C)[C@@]1(C)C[C@@H]2O FBHSPRKOSMHSIF-GRMWVWQJSA-N 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960001882 dexchlorpheniramine Drugs 0.000 description 1
- SOYKEARSMXGVTM-HNNXBMFYSA-N dexchlorpheniramine Chemical compound C1([C@H](CCN(C)C)C=2N=CC=CC=2)=CC=C(Cl)C=C1 SOYKEARSMXGVTM-HNNXBMFYSA-N 0.000 description 1
- 229940120124 dichloroacetate Drugs 0.000 description 1
- JXTHNDFMNIQAHM-UHFFFAOYSA-N dichloroacetic acid Chemical compound OC(=O)C(Cl)Cl JXTHNDFMNIQAHM-UHFFFAOYSA-N 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 229960004704 dihydroergotamine Drugs 0.000 description 1
- HESHRHUZIWVEAJ-JGRZULCMSA-N dihydroergotamine Chemical group C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2[C@@H](C3=CC=CC4=NC=C([C]34)C2)C1)C)C1=CC=CC=C1 HESHRHUZIWVEAJ-JGRZULCMSA-N 0.000 description 1
- MZDOIJOUFRQXHC-UHFFFAOYSA-N dimenhydrinate Chemical compound O=C1N(C)C(=O)N(C)C2=NC(Cl)=N[C]21.C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 MZDOIJOUFRQXHC-UHFFFAOYSA-N 0.000 description 1
- 229960004993 dimenhydrinate Drugs 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- 229960001992 dimetindene Drugs 0.000 description 1
- MVMQESMQSYOVGV-UHFFFAOYSA-N dimetindene Chemical compound CN(C)CCC=1CC2=CC=CC=C2C=1C(C)C1=CC=CC=N1 MVMQESMQSYOVGV-UHFFFAOYSA-N 0.000 description 1
- 229960000520 diphenhydramine Drugs 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229960005178 doxylamine Drugs 0.000 description 1
- HCFDWZZGGLSKEP-UHFFFAOYSA-N doxylamine Chemical compound C=1C=CC=NC=1C(C)(OCCN(C)C)C1=CC=CC=C1 HCFDWZZGGLSKEP-UHFFFAOYSA-N 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 229960001971 ebastine Drugs 0.000 description 1
- MJJALKDDGIKVBE-UHFFFAOYSA-N ebastine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(=O)CCCN1CCC(OC(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 MJJALKDDGIKVBE-UHFFFAOYSA-N 0.000 description 1
- 229960000325 emedastine Drugs 0.000 description 1
- KBUZBQVCBVDWKX-UHFFFAOYSA-N emedastine Chemical compound N=1C2=CC=CC=C2N(CCOCC)C=1N1CCCN(C)CC1 KBUZBQVCBVDWKX-UHFFFAOYSA-N 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- QVDKSPUZWYTNQA-UHFFFAOYSA-N enprofylline Chemical compound O=C1NC(=O)N(CCC)C2=NC=N[C]21 QVDKSPUZWYTNQA-UHFFFAOYSA-N 0.000 description 1
- 229950000579 enprofylline Drugs 0.000 description 1
- 229960003449 epinastine Drugs 0.000 description 1
- WHWZLSFABNNENI-UHFFFAOYSA-N epinastine Chemical compound C1C2=CC=CC=C2C2CN=C(N)N2C2=CC=CC=C21 WHWZLSFABNNENI-UHFFFAOYSA-N 0.000 description 1
- 229960004943 ergotamine Drugs 0.000 description 1
- OFKDAAIKGIBASY-VFGNJEKYSA-N ergotamine Chemical compound C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2C(C3=CC=CC4=NC=C([C]34)C2)=C1)C)C1=CC=CC=C1 OFKDAAIKGIBASY-VFGNJEKYSA-N 0.000 description 1
- XCGSFFUVFURLIX-UHFFFAOYSA-N ergotaminine Natural products C1=C(C=2C=CC=C3NC=C(C=23)C2)C2N(C)CC1C(=O)NC(C(N12)=O)(C)OC1(O)C1CCCN1C(=O)C2CC1=CC=CC=C1 XCGSFFUVFURLIX-UHFFFAOYSA-N 0.000 description 1
- 229960001022 fenoterol Drugs 0.000 description 1
- 229960003592 fexofenadine Drugs 0.000 description 1
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical compound C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 description 1
- 229960000676 flunisolide Drugs 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229960002714 fluticasone Drugs 0.000 description 1
- MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 description 1
- OATDVDIMNNZTEY-DAXLTYESSA-N flutropium Chemical class C[N@@+]1(CCF)[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)C(O)(C1=CC=CC=C1)C1=CC=CC=C1 OATDVDIMNNZTEY-DAXLTYESSA-N 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 229960002462 glycopyrronium bromide Drugs 0.000 description 1
- 229960000708 hexoprenaline Drugs 0.000 description 1
- OXLZNBCNGJWPRV-UHFFFAOYSA-N hexoprenaline Chemical compound C=1C=C(O)C(O)=CC=1C(O)CNCCCCCCNCC(O)C1=CC=C(O)C(O)=C1 OXLZNBCNGJWPRV-UHFFFAOYSA-N 0.000 description 1
- TWTMQRXNAZGSCE-UHFFFAOYSA-N hydron;[6-(methylamino)-1-(2-methylpropanoyloxy)-5,6,7,8-tetrahydronaphthalen-2-yl] 2-methylpropanoate;chloride Chemical compound Cl.C1=CC(OC(=O)C(C)C)=C(OC(=O)C(C)C)C2=C1CC(NC)CC2 TWTMQRXNAZGSCE-UHFFFAOYSA-N 0.000 description 1
- 229950002451 ibuterol Drugs 0.000 description 1
- 230000003116 impacting effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229960001888 ipratropium Drugs 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 229940039009 isoproterenol Drugs 0.000 description 1
- 229960004958 ketotifen Drugs 0.000 description 1
- 229960001120 levocabastine Drugs 0.000 description 1
- ZCGOMHNNNFPNMX-KYTRFIICSA-N levocabastine Chemical compound C1([C@@]2(C(O)=O)CCN(C[C@H]2C)[C@@H]2CC[C@@](CC2)(C#N)C=2C=CC(F)=CC=2)=CC=CC=C1 ZCGOMHNNNFPNMX-KYTRFIICSA-N 0.000 description 1
- 229950008204 levosalbutamol Drugs 0.000 description 1
- 229950008462 lirimilast Drugs 0.000 description 1
- 229960003587 lisuride Drugs 0.000 description 1
- 229960001798 loteprednol Drugs 0.000 description 1
- YPZVAYHNBBHPTO-MXRBDKCISA-N loteprednol Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)OCCl)[C@@H]4[C@@H]3CCC2=C1 YPZVAYHNBBHPTO-MXRBDKCISA-N 0.000 description 1
- JSJCTEKTBOKRST-UHFFFAOYSA-N mabuterol Chemical compound CC(C)(C)NCC(O)C1=CC(Cl)=C(N)C(C(F)(F)F)=C1 JSJCTEKTBOKRST-UHFFFAOYSA-N 0.000 description 1
- 229950004407 mabuterol Drugs 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229960001474 meclozine Drugs 0.000 description 1
- 229950001737 meluadrine Drugs 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 239000004531 microgranule Substances 0.000 description 1
- 229960001144 mizolastine Drugs 0.000 description 1
- 229960001664 mometasone Drugs 0.000 description 1
- QLIIKPVHVRXHRI-CXSFZGCWSA-N mometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CCl)(O)[C@@]1(C)C[C@@H]2O QLIIKPVHVRXHRI-CXSFZGCWSA-N 0.000 description 1
- 229960005127 montelukast Drugs 0.000 description 1
- NPGREARFJMFTDF-UHFFFAOYSA-N n-(3,5-dichloro-1-hydroxypyridin-4-ylidene)-8-methoxy-2-(trifluoromethyl)quinoline-5-carboxamide Chemical compound C12=CC=C(C(F)(F)F)N=C2C(OC)=CC=C1C(=O)N=C1C(Cl)=CN(O)C=C1Cl NPGREARFJMFTDF-UHFFFAOYSA-N 0.000 description 1
- BMKINZUHKYLSKI-UHFFFAOYSA-N n-[2-hydroxy-5-[1-hydroxy-2-[2-[4-[(2-hydroxy-2-phenylethyl)amino]phenyl]ethylamino]ethyl]phenyl]formamide Chemical compound C=1C=C(O)C(NC=O)=CC=1C(O)CNCCC(C=C1)=CC=C1NCC(O)C1=CC=CC=C1 BMKINZUHKYLSKI-UHFFFAOYSA-N 0.000 description 1
- NVOYVOBDTVTBDX-PMEUIYRNSA-N oxitropium Chemical class CC[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)C1=CC=CC=C1 NVOYVOBDTVTBDX-PMEUIYRNSA-N 0.000 description 1
- 229960001972 panitumumab Drugs 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229960004851 pergolide Drugs 0.000 description 1
- YYPWGCZOLGTTER-MZMPZRCHSA-N pergolide Chemical compound C1=CC=C2[C@H]3C[C@@H](CSC)CN(CCC)[C@@H]3CC3=CN=C1[C]32 YYPWGCZOLGTTER-MZMPZRCHSA-N 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229960001190 pheniramine Drugs 0.000 description 1
- 239000002590 phosphodiesterase V inhibitor Substances 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 229960005414 pirbuterol Drugs 0.000 description 1
- 229960003089 pramipexole Drugs 0.000 description 1
- FASDKYOPVNHBLU-ZETCQYMHSA-N pramipexole Chemical compound C1[C@@H](NCCC)CCC2=C1SC(N)=N2 FASDKYOPVNHBLU-ZETCQYMHSA-N 0.000 description 1
- 229960004583 pranlukast Drugs 0.000 description 1
- UAJUXJSXCLUTNU-UHFFFAOYSA-N pranlukast Chemical compound C=1C=C(OCCCCC=2C=CC=CC=2)C=CC=1C(=O)NC(C=1)=CC=C(C(C=2)=O)C=1OC=2C=1N=NNN=1 UAJUXJSXCLUTNU-UHFFFAOYSA-N 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 229960002288 procaterol Drugs 0.000 description 1
- FKNXQNWAXFXVNW-BLLLJJGKSA-N procaterol Chemical compound N1C(=O)C=CC2=C1C(O)=CC=C2[C@@H](O)[C@@H](NC(C)C)CC FKNXQNWAXFXVNW-BLLLJJGKSA-N 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 229960003910 promethazine Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 229950010090 pumafentrine Drugs 0.000 description 1
- MIXMJCQRHVAJIO-TZHJZOAOSA-N qk4dys664x Chemical compound O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O MIXMJCQRHVAJIO-TZHJZOAOSA-N 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 229960002720 reproterol Drugs 0.000 description 1
- WVLAAKXASPCBGT-UHFFFAOYSA-N reproterol Chemical compound C1=2C(=O)N(C)C(=O)N(C)C=2N=CN1CCCNCC(O)C1=CC(O)=CC(O)=C1 WVLAAKXASPCBGT-UHFFFAOYSA-N 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 229960001457 rimiterol Drugs 0.000 description 1
- IYMMESGOJVNCKV-SKDRFNHKSA-N rimiterol Chemical compound C([C@@H]1[C@@H](O)C=2C=C(O)C(O)=CC=2)CCCN1 IYMMESGOJVNCKV-SKDRFNHKSA-N 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 229960001634 ritodrine Drugs 0.000 description 1
- IOVGROKTTNBUGK-SJCJKPOMSA-N ritodrine Chemical compound N([C@@H](C)[C@H](O)C=1C=CC(O)=CC=1)CCC1=CC=C(O)C=C1 IOVGROKTTNBUGK-SJCJKPOMSA-N 0.000 description 1
- 229950004432 rofleponide Drugs 0.000 description 1
- IXTCZMJQGGONPY-XJAYAHQCSA-N rofleponide Chemical compound C1([C@@H](F)C2)=CC(=O)CC[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3O[C@@H](CCC)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O IXTCZMJQGGONPY-XJAYAHQCSA-N 0.000 description 1
- MNDBXUUTURYVHR-UHFFFAOYSA-N roflumilast Chemical compound FC(F)OC1=CC=C(C(=O)NC=2C(=CN=CC=2Cl)Cl)C=C1OCC1CC1 MNDBXUUTURYVHR-UHFFFAOYSA-N 0.000 description 1
- 229960002586 roflumilast Drugs 0.000 description 1
- 229960001879 ropinirole Drugs 0.000 description 1
- UHSKFQJFRQCDBE-UHFFFAOYSA-N ropinirole Chemical compound CCCN(CCC)CCC1=CC=CC2=C1CC(=O)N2 UHSKFQJFRQCDBE-UHFFFAOYSA-N 0.000 description 1
- 229950000366 roxindole Drugs 0.000 description 1
- BKTTWZADZNUOBW-UHFFFAOYSA-N roxindole Chemical compound C=12[CH]C(O)=CC=C2N=CC=1CCCCN(CC=1)CCC=1C1=CC=CC=C1 BKTTWZADZNUOBW-UHFFFAOYSA-N 0.000 description 1
- 229960002052 salbutamol Drugs 0.000 description 1
- 229950001879 salmefamol Drugs 0.000 description 1
- 125000004646 sulfenyl group Chemical group S(*)* 0.000 description 1
- 229950008418 talipexole Drugs 0.000 description 1
- 229960000195 terbutaline Drugs 0.000 description 1
- 229960004558 terguride Drugs 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 239000003848 thrombocyte activating factor antagonist Substances 0.000 description 1
- 229950010302 tiaramide Drugs 0.000 description 1
- HTJXMOGUGMSZOG-UHFFFAOYSA-N tiaramide Chemical compound C1CN(CCO)CCN1C(=O)CN1C(=O)SC2=CC=C(Cl)C=C21 HTJXMOGUGMSZOG-UHFFFAOYSA-N 0.000 description 1
- 229940110309 tiotropium Drugs 0.000 description 1
- 229950003899 tofimilast Drugs 0.000 description 1
- 229960004045 tolterodine Drugs 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 229960000575 trastuzumab Drugs 0.000 description 1
- 229960005294 triamcinolone Drugs 0.000 description 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- BDIAUFOIMFAIPU-UHFFFAOYSA-N valepotriate Natural products CC(C)CC(=O)OC1C=C(C(=COC2OC(=O)CC(C)C)COC(C)=O)C2C11CO1 BDIAUFOIMFAIPU-UHFFFAOYSA-N 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229960004764 zafirlukast Drugs 0.000 description 1
Images
Landscapes
- Containers And Packaging Bodies Having A Special Means To Remove Contents (AREA)
Abstract
An atomiser (1), a reservoir (3) and a method are proposed for the delivery and in particular the atomisation of a formulation (2), particularly a powder. A pump and a spring (14) are arranged inside the annular reservoir, wherein the pump and the spring (14) are moveable radially and in a sliding manner. The pump is actuated by the spring (14) to put air under pressure for discharging powder from the reservoir (3). The reservoir (3) comprises receptacles (4) or cavities each comprising an insert with a respective dose of the formulation (2). The receptacles (4) are constructed as separate parts and/or arranged on a common or annular carrier and/or are sealed separately and/or on its outer circumferential periphery. The spring (14) is tensioned and the air is sucked into the pump. Then, the next receptacle (4) and a connecting element (24) are aligned relative to each other. Finally, the aligned receptacle (4) is pierced by the connecting element for supplying the air.
Description
Technical field
The present invention relates to nebulizer as the preamble of claim 1 or 19, relate to the storage for nebulizer as the preamble of claim 20, and relate to the method for delivery formulation as the preamble of claim 32.
The invention particularly relates to for sucking or sending and atomization for the preparation of other medical treatment or therapeutic use.Especially preferably, the present invention relates to contain specifically sending of at least one active substance or the medical preparation formed by least one active substance, pharmaceutical preparation and/or treatment preparation.
The invention particularly relates to a kind of inhaler.Between atomization period, produce and there is the preferably very meticulous solid in 1 to 10 μ m scope of the suction of being specifically used for and/or mist agent or the spray cloud of liquid particle.
Preparation is preferably powder.Especially preferably, therefore the present invention relates to a kind of powder inhalator.Yet, preferably also comprise liquid according to terms " formulation " of the present invention, term " liquid " should be interpreted as that (especially) comprises solution, suspension, aaerosol solution (mixture of solution and suspension), dispersion liquid, its mixture etc. on than broad sense simultaneously.
Following description is mainly sending and atomization or, for a kind of powder inhalator (although the present invention is not limited to this), description also can be used in particular for other inhalers, nebulizer or dispensing device for powder formulation.
The invention particularly relates to a kind of nebulizer with the preparation through measuring in advance.Particularly, indivedual dosage is included in the independent container such as chamber, foaming bag, insert, capsule etc., and can individually be taken out and atomization.
Background technology
Basically, there are passive type nebulizer and active nebulizer.In the passive type type, the air flow that preparation produces when sucking or breathe via user and discharging.In active type, preparation is discharged and is had nothing to do with breathing during sucking, and can pass through suction process, triggers and sends by so-called respiratory triggering particularly.Particularly, produced the flowing so that delivery formulation of delivery media of air for example or a certain other gases by nebulizer or inhaler self.For reaching this purpose, nebulizer has the delivery apparatus of air pump for example or pressure gas containers.The advantage that active type is better than the passive type type is, in active type, can be independent of user and the sending and atomization of be very easy to reproduction of reaching preparation.
EP0 950 423B1 disclose a kind of for the medium active dispensing device of (particularly, powder), and this dispensing device has a compressed air pump (that is to say piston pump) be incorporated in dispensing device.Dispensing device has a foaming disk, and this foaming disk has a plurality of foaming bags that contain powder that are configured to circle.For activating or open indivedual foaming bags, move axially casing part.
EP1 132 104B1 promptings are a kind of for sending the active dispensing device contained from the medium of at least one medicinal activity material of foamed strip.This dispensing device has one for the fluid of discharging medium (particularly, air) pump, is for following closely (impact spike) and a transverse actuating device setting up the impact that fluid is communicated with between pump and foaming bag, when activating, this transverse actuating device is located the foaming bag and also makes medium discharge with respect to impacting nail.Dispensing device also has a spring, this spring during the first actuation step in tension and can during the second actuation step, by discharging a breech lock, be released into slack position, spring make successively with respect to impact nail locate the foaming bag, by impact nail open foaming bag and air supply to the foaming bag in order to discharge medium.
WO91/06333A1 discloses a kind of active dispensing device with a hollow cylindrical storage, and this storage comprises a plurality of axially extended chamber that contains powder.By axially promoting together dispensing device, compressed air and finally via chamber out of the ordinary, carry air in order to discharge the powder of each dosage in piston pump.
Summary of the invention
Purpose of the present invention is for providing a kind of nebulizer, a kind of storage for nebulizer and a kind of for sending the method for (discharge) preparation, wherein nebulizer out of the ordinary can be very simply, particularly operate intuitively its simple structure and with low cost simultaneously, and/or be of compact construction, particularly low whole height and/or good atomization characteristics.
Above the target of statement is by the nebulizer as claim 1 or 19, solve by the storage as claim 20 or by the method as claim 32.Other are characterized as the theme of dependent claims.
According to an aspect of the present invention, delivery apparatus, energy storage and/or connecting device are configured in the loop configurations of annular storage or container, the preparation that each in this container contains a dosage.This causes simply and especially compact structure.
According on the other hand, delivery apparatus, energy storage and/or connecting device can be linear, radially and/or sliding type moves and/or can move together.This contributes to simple and/or compact structure.
According to another aspect, the delivery media that makes of nebulizer structure can be stored and is under pressure so that delivery formulation by energy storage or spring.Very good atomization characteristics is very simply constructed and is made it possible to reach in this permission, is independent of particularly breathing or the suction of sufferer and/or is independent of the actuating of sufferer and reaches equal atomization characteristics.
Of the present invention is the storage that has a plurality of containers for a kind of more on the one hand, this container comprises respectively insert, wherein this container structure is independent part and/or be configured on common or annular region, and/or sealing and/or seal on its exterior periphery periphery individually.This contributes to simple and/or compact structure.In addition, can reach very good atomization characteristics.
According to another aspect of the invention, the force compresses stored by spring for example delivery media and/or the pressure of air makes delivery media pass through container out of the ordinary.This obtains each atomization characteristics very uniformly of sending or discharging.
According on the other hand, spring is stored in tension and/or by the delivery media suction pump, next container is relative to each other aimed at Connection Element, and finally by Connection Element, sting the container that passes aligning with for supplying with delivery media, that is to say, the container pierced through for hanging oneself is discharged or each dosage of atomization.This allows very simple and/or compact structure.In addition.Very simple and easy operation is possible.
The accompanying drawing explanation
Fig. 1 illustrates the schematic cross-sectional according to the nebulizer proposed in transmission location of the first embodiment;
Fig. 2 illustrate according to Fig. 1 in the schematic cross-sectional of the nebulizer of starting state;
Fig. 3 illustrates in opening or the perspective view of the nebulizer of starting state;
Fig. 4 a illustrates the schematic diagram according to the rail plate in the nebulizer of Fig. 1;
Fig. 4 b illustrates the schematic diagram of opening or excise a part of nebulizer with ratchet mechanism according to Fig. 1;
Fig. 4 c illustrates the schematic cross-sectional according to the nebulizer with locking device of Fig. 1;
Fig. 4 d illustrates the perspective view according to the control loop of the locking device of Fig. 4 c;
Fig. 4 e illustrates another schematic cross-sectional according to the nebulizer with locking device of Fig. 4 c;
Fig. 5 illustrate according to Fig. 1 send or atomization after the schematic cross-sectional of nebulizer;
Fig. 6 illustrates the schematic cross-sectional according to the nebulizer proposed in transmission location of the second embodiment;
Fig. 7 illustrate according to Fig. 6 in starting or the schematic cross-sectional of the nebulizer of open mode;
Fig. 8 illustrate according to the 3rd embodiment in opening or the schematic cross-sectional of the nebulizer proposed of starting state;
Fig. 9 illustrates the schematic diagram according to the nebulizer proposed in transmission location of the 4th embodiment;
Figure 10 illustrate according to Fig. 9 in the schematic cross-sectional of the nebulizer of latch mode not;
Figure 11 illustrates the schematic cross-sectional according to the nebulizer of the state in starting, being pressed together of Fig. 9;
Figure 12 illustrates the schematic cross-sectional according to the nebulizer proposed in transmission location of the 5th embodiment;
Figure 13 illustrate according to Figure 12 in the schematic cross-sectional of the nebulizer of latch mode not;
Figure 14 illustrate according to Figure 12 in starting, the schematic cross-sectional of the nebulizer of coarctate state;
Figure 15 illustrates the schematic cross-sectional according to the nebulizer proposed in transmission location of the 6th embodiment;
Figure 16 illustrate according to Figure 15 in the schematic cross-sectional of the nebulizer of latch mode not;
Figure 17 illustrates the schematic diagram according to the Connection Element of the nebulizer of Figure 16;
Figure 18 illustrates another exemplary details from Figure 16;
Figure 19 illustrates the side view according to the details of the nebulizer in transmission location with enumerator of Figure 15;
Figure 20 illustrate corresponding to Figure 19 in the side view of the nebulizer of latch mode not;
Figure 21 illustrates the perspective view according to the nebulizer with timer of Figure 15;
Figure 22 illustrates the perspective view according to the nebulizer with medicine container of Figure 15;
Figure 23 illustrates the schematic cross-sectional according to the nebulizer proposed in transmission location of the 8th embodiment;
Figure 24 illustrate according to Figure 23 in opening or the schematic cross-sectional of the nebulizer of starting state;
Figure 25 illustrates the schematic diagram according to the transmitting device of the nebulizer of Figure 23;
Figure 26 illustrates the schematic diagram according to the part of the nebulizer proposed of the 9th embodiment;
Figure 27 illustrate corresponding to Figure 26 in the view of the nebulizer of starting state;
Figure 28 illustrates the schematic functional representation according to the nebulizer proposed of the tenth embodiment; And Figure 29 illustrates the schematic cross-sectional according to the nebulizer of Figure 28.
At Zhu Tuzhong, same reference numbers is for identical or like parts, even the description that does not repeat to be associated.Particularly, obtain whereby identical or corresponding advantage and character.
The main element symbol description
1 nebulizer
2 preparations
3 storages
4 containers
5 delivery apparatus
6 pump chambers
7 retractable sacks
8 mouthpieces
9 grids
10 covers
11 delivery sides to
12 axis
13 shells
14 springs
15 gears
16 have screw shell
17 female threads
18 external screw threads
19 inner meshing parts
20 lock arms
21 actuation elements
22 engaged elements
23 transmitting devices
24 connecting devices
25 external engagement parts
26 control cam
27 outthrust
The 27a ratchet
The 27b transfer arm
28 inserts
29 take in chamber
30 openings
31 storage chamber
32 passages
33 finger pieces
34 Connection Elements
35 send passage
36 rotating retainers
37 locking devices
38 breech locks
39 control loops
The 40a lock arm
40b lock arm (shell)
The 40c retainer
The 40d stopper arms
The 40e slidingsurface
41 inner bodies
42 carriages
43 teeth
44 coordinate tooth
45 peripheral openings
46 relieving mechanisms
47 upper case parts
48 lower case parts
49 spring elements
50 snap fit hooks
51 annular shoulders
52 entrances
53 outlets
54 arrows
55 loop brackets
56 dimples
57 blocking vessels
58 bearings
59 enumerators
60 scales
61 windows
62 dimples
63 clocks
64 lids
65 interface channels
66 pinions
67 internal tooths
68 control elements
69 axially engagements
70 first rail plates
71 first engaged elements
72 first sections
73 second sections
74 the 3rd sections
75 second rail plates
76 second engaged elements
77 bearings
78 shoulders
79 slide plates
80 radial components
81 hlding parts
The specific embodiment
Fig. 1 illustrates the nebulizer proposed 1 in transmission location according to the first embodiment with schematic cross-sectional.Particularly, nebulizer 1 is for especially being preferred for the preferred portable type inhaler of mist agent treatment.
Preparation 2 is the indivedual dosage that suck that are specifically used for for being sent in succession by nebulizer 1 through metering in advance preferably.
Particularly, delivery apparatus 5 has a pump chambers 6, and pump chambers 6 is preferably formed, delimits and/or changed by retractable sack 7 and/or a certain other elements of delivery apparatus 5.
Use delivery apparatus 5, particularly, surrounding air can be used as delivery media and is absorbed into and is under pressure.Use delivery media, can be when activating or use nebulizer 1 (particularly, only after corresponding triggering nebulizer 1) discharge preparations 2 from container 4, that is to say the preparation 2 of a dosage.Yet, delivery apparatus 5 in theory can also a certain other modes produces, provides and/or pressurize as the air of delivery media, other gases or liquid even, so that delivery formulation 2 is as the mist agent with preferred finely particulate (solid and/or liquid) or spraying mist particularly.
The opening of sending of mouthpiece 8 optionally possesses grid 9 or other protective elements, special in order to can prevent for example, the damage to nebulizer 1 (, storage 3 or container 4) caused by external effect etc., and/or prevents the discharges such as other parts, larger microgranule.
Particularly, cover 10 can be with indicated delivery side in Fig. 2 to 11 mobile with meeting at right angles, particularly, and slidably and/or rotatable.
In the example embodiment, cover 10 and preferably can or rotate around the pivot center rotation of the central axis 12 of the loop configurations of nebulizer 1 or storage 3 or container 4 or storage 3.Nebulizer 1 or its shell 13 be particularly with respect to axis 12 rotation-symmetric at least in fact preferably, and/or structure is at least to be essentially smooth or plate-like, particularly the shape of rounded in fact dish.Yet other geometry and structure solution and configuration are also possible.
Fig. 3 illustrates a preferable configuration of nebulizer 1, particularly, and one smooth, plate-like and/or circular embodiment.Same apparent, cover 10 coverings or overlapping nebulizer 1 preferably at least 90 °, the in fact about circumferential section of 150 ° to 170 ° particularly, particularly on peripheral direction and from a planar side via this circumferential section to another planar side.Yet other structure solutions and configuration are equally also possible herein.
In shown embodiment, in the fully open position shown in Fig. 2 and Fig. 3, cover 10 and preferably rotate or rotate approximately 150 ° to 180 ° with respect to the transmission location of closing shown in Fig. 1.Yet other anglecs of rotation are also possible.
Perhaps, cover 10 can be for example with the mode of slide plate and/or baffle plate form and can be for example by shell 13 or mouthpiece 8 guide, installation or fixing.
Energy storage or spring store and can drive various devices and/or for different purposes, and be specifically used for driving delivery apparatus 5 or delivery media be under pressure or delivery media is shifted out from pump chambers 6, in order to discharge the preparation 2 of corresponding dosage and then make its atomization via the container transport delivery media and in wanted mode.Preferably only during delivery formulation 2 or for delivery formulation 2, delivery media is under pressure.Yet in theory, this also can occur in advance, under this situation, provide valve gear or similar device (not shown), particularly with prevent reality desired send and atomization before send too early delivery media and preparation 2.
Energy storage preferably is associated with delivery apparatus 5 or forms a part of delivery apparatus 5.Especially preferably, energy storage or spring store around delivery apparatus 5 or are configured or are incorporated in delivery apparatus 5.
In the embodiment with shown in example, after spring 14 is arranged on and extends axially or be arranged on pump chambers 6 or retractable sack 7 with respect to the direction of pump or pumping action.Under this situation, spring 14 preferably serves as Compress Spring, its compression or driving pump chamber 6 or retractable sack 7 or mobile for example piston (not shown), in order to reduce contained delivery media in the size of pump chambers 6 or compressor pump chamber 6, that is to say, delivery media is under pressure, and reaches whereby sending of delivery media.
According to the present invention, delivery apparatus 5 and/or energy storage or other devices are configured in and in the loop configurations of storage 3 or container 4, also make delivery apparatus 5 and/or energy storage to extend axially to exceed storage 3 or container 4, or in example transmission location as shown in FIG. 1, make delivery apparatus 5 and/or energy storage can be configured in the axial dipole field position of the principal plane of storage 3 or planar annular.
As hereinafter be described in more detail, cover 10 rotation axis preferably corresponding to the axis 12 of the loop configurations of storage 3 or container 4, storage 3 preferably can rotate around this axis.
Preferably, gear 15 partly or entirely is configured in the loop configurations of storage 3 or container 4.This promotes again the tight structure of nebulizer 1.
Especially preferably, by opening and/or closing movement of cover 10, gear 15 produces axially-movable with respect to loop configurations and/or axis 12 particularly.Especially preferably, axially-movable is extended or 12 extensions of paralleling to the axis on axis 12 or along axis 12.It is that at least one component of the motion that produced by gear 15 on the power outlet side extends on axial direction mentioned above that term " axially-movable " is interpreted as the meaning.
The axially-movable that can be produced by gear 15 especially be preferred for opening next container 4, for mobile and/or reach storage 3 or container 4, for back-moving spring store, for example, for activating delivery apparatus 5 (being specifically used for being absorbed into air) and/or another device (, enumerator) for activating nebulizer 1.Preferably, gear 15 has for driving the different drive ratios of different device on the power outlet side.
Screw thread or have screw shell 16 preferably couple directly or indirectly or be connected to cover 10 and/or with the rotation axis arranged coaxial of cover 10, or form the rotation axis of cover 10.Particularly, cover 10 driving and directly cause have screw shell 16 to rotate.
In shown embodiment, delivery apparatus 5 and particularly and energy storage can preferably drive in the axial direction or activate via female thread 17 by gear 15 (particularly).Female thread 17 preferably with inside meshing part 19 engagements that comprise particularly a complementary threads part or other outthrust, mating surface etc., make the rotation of screw shell 16 cause the axially-movable of the nonrotational meshing part 19 be associated with delivery apparatus 5 or energy storage.
Particularly, spring 14 is at one end such as by means of end plate etc. and be supported on the meshing part 19 that is preferably formed corresponding spring base or bearing, and is coupled to the retractable sack 7 of delivery apparatus 5 or the movable terminal of other pumping elements at other end place.Yet different structure solutions is also still possible.Particularly, gear 15 or meshing part also can only directly act on retractable sack 7 or other pumping elements, and only indirectly are coupled in addition spring 14 or are not coupled to spring 14 fully.
From the transmission location shown in Fig. 1, when cover 10 is opened, on the one hand, meshing part 19 moves axially, that is to say, it carries out preferred axially-movable, and on the other hand, preferred chain and/or releasable connection part between meshing part 19 and delivery apparatus 5 and/or spring storage (for example, by means of at least one lock arm 20) the transmission axially-movable, and cause that particularly pump chambers 6 increases in the axial direction and preferably is absorbed into surrounding air, retractable sack 7 is pulled in the axial direction to be opened or increases, and/or preferred disposition at center or the actuation element 21 of axial arrangement be released and/or axially outwards shift out (especially when reaching the axial end position), as shown in the end position in Fig. 2.Through the spring 14 of tension, preferably with together with the axial end of meshing part 19 and retractable sack 7, move axially.
Between the follow-up period of energization of actuation element 21, particularly by radially inwardly pressing, initial send and atomization from the preparation 2 of adjacent vessel 4.Particularly, meshing part 19 on the one hand with at least one lock arm 20 between be connected or on the other hand with delivery apparatus 5 and/or energy storage between be connected particularly because at least one engaged element 22 springs at least one lock arm 20 fact of disengaged orientation (radially inside in shown embodiment) and sets up.As hereinafter discussed more in detail, spring stores or then causes that retractable sack 7 is compressed and make pump chambers 6 less through resilience or the spring force of back-moving spring 14, as its result, in pump chambers 6, contained delivery media (particularly, surrounding air) be under pressure and be moved out of, thereby preparation 2 is discharged from and atomization in wanted mode.
Replace screw thread or, except screw thread, can use in theory a certain other to control cams, slope, clinoplain or other gear drives and connect, to reach particularly motion sequence as described above, hereinafter described motion sequence and/or a certain other motion sequences.
Preferably, by covering 10 opening and/or closing, drive or activate particularly transmitting device 23 and/or connecting device 24 via gear 15.Especially preferably, reuse the axially-movable produced by gear 15.
In shown embodiment, the actuating of the actuating of transmitting device 23 and connecting device 24 (that is to say, storage 3 is moved forward to next container 4 and open next container 4 and/or be attached to delivery apparatus 5) is combined or is coupled.Yet these activate also can be controlled independently of one another or be controlled via the independent driving of gear 15 or independent drive chain particularly.
The combination of preferably, reaching transmitting device 23 and connecting device 24 by means of the external engagement parts 25 of the engagement of the external screw thread 18 with screw shell 16 is arranged (particularly via corresponding have threaded portion, slidingsurface etc.) drives.This meshing part 25 is connected to non-rotatingly specifically the storage 3 of preferred annular or is formed by storage 3.For instance, meshing part 25 can form a sealing internal ring of storage 3.Yet this meshing part 25 is not indispensable.For instance, storage 3 also can be via corresponding slidingsurface etc. and with directly engagement of gear 15 (external screw thread 18 that screw shell 16 is arranged particularly).
Rotation has screw shell 16 or external screw thread 18 (or other control cam) to cause non-common engagement in rotation parts 25 and the therefore axially-movable of storage 3.For instance, during cover 10 open and as the result of opening of cover 10, that is to say, by means of gear 15, the axial location of storage 3 in the transmission location shown in Fig. 1 with container 4 moves axially to the position shown in Fig. 2.In shown embodiment, on this axially-movable or the lifter motion direction contrary in the axially-movable with for activating delivery apparatus 5 (particularly, being absorbed into surrounding air), carry out but also can carry out on same direction.
Only after actuation element 21 has activated, (that is to say, after sending the preparation 2 of also atomization from container 4) and again close cover 10.Close cover 10 and screw shell 16 is rotated and cause that storage 3 carries out contrary axially-movable or lifter motion again.In this axially-movable process and/or opening in the opposite shaft orientation motion of cover during 10, rail plate causes storage 3 container 4 ground reaches or further rotate (that is to say, to next container 4) one by one.
The possible structure configuration of the preferred rail plate formed by the inwall of shell 13 of Fig. 4 a explanation or control flume or control cam 26, in order to carry out desired preferably alternately axially-movable and the storage 3 progressively further rotation of container 4 one by one of storage 3.Particularly, this aggregate motion is reached by the extension, diagonal angle that alternately axially reaches of controlling cam 26, and for example, the outthrust of storage 3 radially is engaged in this part.Yet other inner radial and/or axial means are also possible.
In shown embodiment, external engagement parts 25 and above-mentioned rail plate form transmitting device 23 or its assembly.Particularly, rail plate or transmission mechanism are constructed (reciprocal axial motion causes progressively rotation) in the mode of ball point pen mechanism.Yet other structure solutions be also possible, this structure solution causes storage 3 progressively to move forward or further rotation, especially preferably axially-movable and/or the rotation of the gear assembly by screw shell 16 is for example arranged on container 4 ground one by one particularly.
According to the alternate embodiment shown in Fig. 4 b, replace rail plate or control cam 26 or except rail plate or control cam 26, transmitting device 23 can have ratchet mechanism or the bolt latch mechanism 27 that (particularly) allows storage 3 progressively move forward or further rotate, and this storage 3 is shown in the drawings to be opened or to cut away a part.Ratchet mechanism 27 is formed between external engagement parts 25 and annular storage 3 particularly, and both can relative to each other rotate by corresponding ratchet step (ratchet step) on a direction to make this.
In shown embodiment, ratchet mechanism 27 has a ratchet 27a particularly, and transfer arm 27b can mesh in this ratchet 27a.Especially preferably, the locking radial engagement occurs.Yet on principle, engagement also can occur in the axial direction.Preferably, ratchet mechanism 27 is formed on inside and/or forms around storage 3.Transfer arm 27b can especially preferably move in an alternating manner by delivery apparatus 5 (gear 15 particularly).In shown embodiment, transfer arm 27b directly or indirectly has been connected to screw shell 16, is formed on particularly on external engagement parts 25.Preferably, transfer arm 27b towards ratchet 27a elastic biasing (particularly, by its intrinsic elasticity) to produce desired locking mesh.Especially preferably, provide a plurality of transfer arm 17b with by covering 10 or the reciprocating motion of screw shell 16 is arranged or rotate the desired reliably progressively motion obtain storage 3.
Now will be described in more detail the preferable configuration of connecting device 24.Yet, for ease of understanding, at first will be explained in more detail the preferred embodiment of storage 3.
For the structure and configuration of storage 3 and container 4, there are various probabilities.For instance, it can be optionally the foaming configuration with the combination such as carriage.Then for example by the foaming bag, form indivedual containers 4.
Especially preferably, by insert 28, form container 4, this insert 28 be contained in storage 3 preferably separately, the guide rail that radially extends particularly or take in chamber 29.Particularly, but the preferred radial displacement of each insert 28 or movement.
In shown embodiment, particularly, insert 28, take in chamber 29, mouthpiece 8 and/or delivery apparatus 11 arranged radiallys.Yet, also may there is in theory different the arrangement, for example, axially-aligned.
Take on the outer periphery that chamber 29 preferably is provided at storage 3 with opening 30 or loop configurations, when do not use or in as during state while supplying with, this opening 30 is preferably and closes, particularly sealing or otherwise be closed or cover.Reference marker 30 indications in Fig. 1 such as corresponding sealing, paper tinsel, thin film.As state while supplying with in, contain insert 28 take in chamber 29 each particularly with fluid sealing mode and also may seal with air tight manner with being hedged off from the outer world.Storage 3 is made by the non-proliferation plastics particularly and/or is optionally possessed the diffusion outer enclosure.
Each insert 28 has a storage chamber 31, the dosage that it contains specific insert 28 or preparation 2 and be filled with preparation 2 particularly during factory manufactures storage 3 or nebulizer 1.Pipeline in insert 28 or passage 32 preferably with storage chamber 31, be connected with for sending, atomization and/or remove coalescent preparation 2.Passage 32 can (if necessary) be integrated with in nozzle (not shown) or form this nozzle.In shown embodiment, therefore insert 28 is formed for the container 4 of preparation 2 with its storage chamber 31, or insert 28 is accommodated in and takes in chamber 29 or container 4 what form in storage 3 or formed by storage 3.
For delivery formulation 2, open container 4 out of the ordinary.In shown embodiment, this preferably delivery end by particularly via opening 30 by insert 28 parts out of the ordinary shift out its take in chamber 29 and preferably via opening 30 radially outward promote the sealing etc. (not shown) carry out.In this way, take in that chamber 29 or its opening 30 are opened and passage 32 exposes.For instance, (not shown) such as sealed foils of sealing respective openings 30 tears off from insert 28, or another closure or the coating member of sealing opening 30 are moved, open, release or otherwise remove from insert 28.
In shown embodiment, distinctly take in preferably moving radially preferably of chamber 29 inserts 28 and carry out by means of connecting device 24 or transmitting device 23 for opening, in the zone of the finger piece 33 by making connecting device 24 or the inner radial end of other actuated components in insert 28 out of the ordinary, axially thrust particularly particularly take in chamber 29 and particularly the desired outward radial by corresponding slidingsurface (on finger piece 33 and/or insert 28) execution insert 28 move to carry out.
For example, because storage 3 has enough thin wall or have frangible point in thrusting zone, therefore thrusting of finger piece 33 is possible.Perhaps, storage 3 also can comprise an opening etc., and it is sealed, cover or possess closure and can be opened or be thrust by finger piece 33.
Fig. 1 with the cross section on left side illustrate still close take in chamber 29, wherein insert 29 is not yet radially outward promoted.Fig. 2 be illustrated on outlet side, be opened take in chamber 29, the insert 28 wherein moved radially is outstanding from opening 30.
In this embodiment, connecting device 24 has one for container 4 out of the ordinary, setting up the Connection Element 34 be communicated with for the fluid of supplying with delivery media, make particularly and can for example (that is to say via container 4 out of the ordinary via the passage 35 of sending as by as shown in delivery apparatus 5, insert 28 out of the ordinary or its storage chamber 31) Connection Element 32 supply with delivery media, thereby for the preparation of sending each dosage and the preparation that is specifically used for each dosage of atomization.
Fluid is communicated with preferably also to be set up with respect to the axially-movable of shell 13 or Connection Element 34 by storage 3.Particularly, finger piece 33 at first axially is engaged on and distinctly takes in chamber 29 so that mobile next by the insert 28 used in the radial direction.After this radial motion, along with axially-movable continues, Connection Element 34 is engaged on to be taken in chamber 29 and is engaged in insert 28.For this reason, Connection Element 34 is configured to pierce through element particularly, for example be and there is corresponding most advanced and sophisticated intubate or the form of pin so that particularly auxiliary carry out storage chamber 31 pierce through or other thrust to set up desired fluid and are communicated with.Thereby, provide delivery media to the fluid of storage chamber 31 be communicated with and delivery media can be supplied to storage chamber 31 to discharge preparation 2.
In shown embodiment, external engagement parts 25, finger piece 33 and Connection Element 34 form connecting device 24 or its assembly.Yet, other structure solutions are possible, with for opening or pierce through with connecting this container 4 or optionally opening or sting the container 4 be through on supply side and/or on outlet side, and/or for this container 4 is connected to delivery apparatus 5, or be communicated with for the direct supply of surrounding air or another fluid of suction for for example setting up, and be specifically used for preferably radially (but optionally also axial) mobile relevant insert 28, for opening the respective openings 30 of taking in chamber 29 and/or the supply that is connected to delivery media for the storage chamber 31 by insert 28, be specifically used for Connection Element 34 is inserted in storage chamber 31.
In shown embodiment, particularly, axially-movable causes and opens, connects or pierce through via connecting device 24, preferably with the delivery side to 11 or the throughput direction of container 4 or motion or the rotation direction of storage 3 meet at right angles.Particularly, carry out and axially connect or pierce through in shown embodiment.Yet radially or other connections or also pierce through basically as possible, and (if necessary) also can be provided by means of the axially-movable that is provided by gear 15 or carry out for this.
In theory, the direction 11 that connects, opens, pierces through and/or send can radially be moved.
Especially preferably, connecting device 24 (particularly as delivery apparatus 5 and/or transmitting device 23) can by opening and/or closing, cover 10 activates and/or can activate by preferred common gear 15 or at least one axially-movable.
Another feature according to hereinafter explaining referring to alternate embodiment, also may be configured in transmitting device 23 and/or connecting device 24 in the loop configurations of storage 3 or container 4.The axial height that this promotes again the especially compact structure of nebulizer 1 and contributes to particularly to minimize nebulizer 1.
Fig. 2 illustrates the nebulizer 1 in starting state.Surrounding air is inhaled in pump chambers 6.Spring 14 is tightened up.The container 4 of selecting for sending next dosage has been opened and has connected, and corresponding insert 28 has radially outward been promoted and be connected to by means of Connection Element 34 (being pierced through by Connection Element 34 particularly) supply of delivery media.
In shown embodiment, the actual delivery of taking in preparation contained in chamber 29 2 or dosage through piercing through and particularly atomization after only can corresponding triggering or further activate (for example, cover 10 another or further activate after) but as the result of actuation element 21, occur particularly, actuation element 21 is preferably only axially outwards mobile under this state, is axially inwardly pressed and is activated by user or sufferer (not shown) particularly.This latch or other mesh components, make spring store or spring 14 can relax.Delivery media in pump chambers 6 is under pressure and is delivered to via sending passage 35 and Connection Element 34 and connects in storage chamber 31.Delivery media continues to flow through passage 32 and flows out insert 28, and in storage chamber 31, contained preparation 2 is discharged from simultaneously.The agent of gained mist or spray cloud are sent via mouthpiece 8 via selecting grid 9, make user or sufferer to suck to have sent and the preparation 2 of atomization particularly.
The nebulizer 1 of (that is to say,, container 4 lax at spring 14 is empty and covers 10 and still open in situation) after Fig. 5 illustrates suction with schematic cross-sectional.
After sucking or after delivery formulation 2, again close cover 10.This completes particularly on contrary rotation direction.Due to provided coupling (particularly, by means of gear 15), inner meshing part 19 moves back into it in the axial direction again in the original position shown in Fig. 1, spring storage simultaneously or spring 14 are strained again, and finally re-establish that the operation between storing of meshing part 19 and delivery apparatus 5 or spring is connected or other axially connect (particularly via latch walls 20), make spring 14 relax and in the situation that meshing part 19 be connected and re-establish the original position shown in Fig. 1 with will keep between retractable sack 7 and/or spring 14 particularly.In addition, storage 3 moves back into its axial home position, that is to say, is axially promoted back in the opposite direction.Particularly, this discharges storage 3 from finger piece 33 and from Connection Element 34.
When connecting device 24 (its finger piece 33 and Connection Element 34 particularly) no longer is engaged in storage 3 but allows desired rotational motion, storage 3 reach or the further rotation of container one by one preferably is superimposed upon in axially-movable, and this (that is to say, opening and/or the down periods of cover 10) and occurs all the time during cover 10 move up and down.In shown embodiment, rail plate or control cam 26 therefore preferably through design make storage 3 one by one container 4 to move forward or further rotate the only part in axially-movable during occur.
Measure described above obtain having particularly a small amount of assembly nebulizer 1 very closely, simple structure.
The nebulizer 1 proposed can very simply and intuitively operate.In essence, operation nebulizer 1 is needed only for opening and cut out cover 10.The all functions of imagination or process are triggered whereby or control or automatically occur.Except the actuating of cover 10, when nebulizer 1 is configured to active nebulizer 1, it triggers actual delivery and atomization after only remaining on and opening cover 10.This preferably completes by activating (pressing particularly) actuation element 21.Because actuation element 21 only is preferably, at nebulizer 1, be activated (that is to say, cover 10 and be opened) afterwards actuatable, axially shift out and/or can approach, therefore make simple intuitive operation become and may and get rid of maloperation.
After suction, can again close nebulizer 1 or cover 10.Preferably, as long as actuation element 21 not yet activated, that is to say, in shown embodiment still in axially extended position, or oneself be opened connect or container 4 delivery formulations 2 that pierce through before, cover 10 against closure and fastening.
Fig. 3 illustrates in opening or the nebulizer proposed 1 of starting state.Therefore cover 10 rotates approximately 160 ° to 180 ° with respect to the transmission location of closing shown in Fig. 1.Preferably can be only in the opposite direction rotating mask 10 to open and to close cover 10.Therefore rotating retainer 36 preferably is provided, and it gives prominence to from periphery or shell 13 as seen and for example from the outside in shown embodiment.This contributes to guarantee simply and intuitively operating of nebulizer 1, because user is understood cover 10 intuitively, must open or close how many and open or close in which direction.Especially preferably, nebulizer 1 structure make rotating retainer 36 be formed for cover 10 in open mode and also for the retainer of the cover 10 in closed condition.Perhaps, also can provide for this purpose independent outthrust or retainer.
Preferably, nebulizer 1 or locking device 37 are included in the control loop 39 illustrated separately with perspective view in Fig. 4 d.Control loop 39 its axially or planar side there is tooth or breech lock 38 on both.Reach as shown in Figure 1, Figure 2 shown in Fig. 4 c, control loop 39 is guided in circular passage in nebulizer 1 or its shell 37 etc. particularly in a rotatable manner.
As indicated in Fig. 4 c, in shell side is locked and determined breech lock 38 that arm 40a is engaged on control loop 39, during on the cover side, lock arm 40b is engaged on another breech lock 38 simultaneously.Breech lock 38 matches each other so that covering 10 initially only can move in one direction or rotate with respect to shell 13 with lock arm 40a and 40b, and therefore by locking device 37 or by lock arm 40a or 40b, works in the opposite direction and prevent rotation in the opposite direction.
Preferably, provide a plurality of lock arm 40a on shell 13, it is engaged in the associated breech lock 38 of control loop 39 and allows control loop 39 only to rotate in one direction with respect to nebulizer 1 or shell 13.Therefore, preferably also on cover 10, configure some lock arm 40b or some lock arm 40b are associated with cover 10, and this lock arm 40b allows control loop 39 only rotating on a rotation direction with respect to cover 10.
For guaranteeing that covering 10 only alternately opens or closes fully, control loop 39 is with respect to shell 13 or cover 10 and only may rotation in one direction under any situation can alternately be blocked and if only if arrive end position out of the ordinary (that is to say, in fully open position or fully closed position) time and restart or release.Hereinafter will be referring to another cross section brief explanation control loop 39 of the nebulizer 1 according to Fig. 4 e with respect to shell 13 or cover this locking of 10.
Form the retainer 40c as shown in Fig. 4 d on control loop 39, it is cooperated with the stopper arms 40d as shown in Fig. 4 e.Fig. 4 e illustrates the locking of control loop 39 to prevent the rotation with respect to shell 13 with example.Carry out this locking with correspondence or similar fashion between cover 10 and control loop 39, and this is locked in during covering 10 reverse motions with respect to shell 13 and works.
In above-mentioned locking, at least one retainer 40c hits at least one stopper arms 40d, make control loop 39 also be blocked with respect to the rotation of shell 13, control loop 39 may enter not in the rotation direction of lock arm 40a and 38 blocking-up of associated breech lock thereof with respect to the rotation of shell 13 originally.Keep this by the blocking-up of stopper arms 40d, until cover 10, to move to its end position.
When arriving end position, the control inclined-plane or the slidingsurface 40e that are formed on cover 10 cause stopper arms 40d springing, make the retainer 40c of previous blocking-up now be released, and therefore cover 10 and can return with respect to control loop 39 and therefore also rotate in the opposite direction or move.Simultaneously, at this end position, another retainer 40c (not shown in Fig. 4 e) of control loop 39, in abutting connection with the stopper arms 40d be configured on cover 10, blocks the relative turnability of control loop 39 with respect to cover 10 whereby.As a result, cover 10 now can only rotate in the opposite direction or move until arrive other end position together with control loop 39.In other end position, correspondingly again block the rotation of control loop 39 with respect to shell 13, and to cover 10 turnability with respect to control loop 39 be again freely.Therefore, cover 10 and only alternately open or close fully, in order to guarantee simply and operation intuitively or activate and particularly so that the operation of debug.
Shown embodiment illustrates active nebulizer 1.Yet in theory, nebulizer 1 also can be configured to the passive type nebulizer.Under this situation, can save delivery apparatus 5 and/or energy storage or spring and store.Instead, for instance, can during sucking, by respiratory movement, be absorbed into surrounding air, and by this air via container 4 out of the ordinary (particularly, the access portal 30 of the insert 28 of taking in chamber 29 and using) be delivered to mouthpiece 8, make in wanted mode and send or discharge and atomization preparation 2.
If necessary, also can be independent of delivery apparatus 5 and the storage of use spring, for example, for moving forward and/or opening or closing container 4, be specifically used for driving and/or activate transmitting device 23 and/or conveyer device 24.
If nebulizer 1 does not have delivery apparatus 5 and/or energy storage, can omit actuation element 21 and needed actuating except mobile cover 10 (that is to say the actual release of preparation 2 and the additional triggers of atomization).More suitably, then preferably be enough to open cover 10 in order to start nebulizer 1, make that next container 4 is ready to be directly used in and to suck and suck and can occur immediately with its dosage or preparation 2.
The nebulizer 1 proposed preferably comprises an enumerator (not shown) in addition.
The preferred Purely mechanical operation of the nebulizer 1 proposed.
The nebulizer 1 proposed preferably only is comprised of plastic assembly or part at least in essence, or at least only is made of plastics in essence.If necessary, only spring 14 and optionally grid 13 can be made of metal.
According to another feature, also can omit in the first embodiment particularly by pressing effectively sending and the manual activation of atomization of preparation 2 that actuation element 21 carries out.Instead, preferably provide the actuating by breathing to control.For instance, when by breathing, in nebulizer 1, producing corresponding vacuum, can not set up inner meshing part 19 on the one hand with the spring 14 of biasing between fixing be connected or on the other hand with retractable sack 7, another conveying or pumping element etc. between fixing be connected, so that make preparation 2 to send and particularly the atomization of preparation 2 (that is to say, by means of being stored in energy storage or the spring energy in storing) can be during sucking occurs in fact automatically.
Some extra embodiments of proposed nebulizer 1 hereinafter will be described, difference or the new aspect wherein only emphasizing to compare with the first embodiment in essence.Therefore the explanation provided in above and annotation are preferably still with its original meaning application or to augment or the similar type application.
Fig. 6 and Fig. 7 illustrate the schematic diagram of the second embodiment of proposed nebulizer 1.Fig. 6 is illustrated in container 4 and does not pierce through nebulizer in the closed position in situation 1.It is opened or pierce through the nebulizer in starting state 1 in situation that Fig. 7 is illustrated in container 4.
In the second embodiment, form contrast with the first embodiment, storage 3 can not move axially.Instead, connecting device 24 preferred axes are to slidably or removable.In shown embodiment, by rotatable inner body 41, carry out fixing storage 3.Connecting device 24 (at least its Connection Element 34 and preferably its finger piece 33) is arranged on axially movable but non-rotatable carriage 42.Carriage 42 is preferably axially movable by opening and/or cut out cover 10 (particularly by means of not detailed illustrated gear 15) herein again.
In the second embodiment, carriage 42 on inner body or around inner body and preferably coordinate along periphery with storage 3, and with carriage 42, above the end face of the inner body 41 of the outside around storage 43 extends to the other end of storage 3 and radially inwardly is back to, be formed with particularly preferred axial tooth 43 internal edge mode and coordinate.Carriage 42 has a peripheral openings 45, and it at least is positioned on the extension of the special container 4 that has been opened or has pierced through or the insert 28 radially moved forward, so that sending of preparation 2 can be carried out and not get clogged in starting state.
In the second embodiment, use the operation sequence identical with operation sequence in the first embodiment.
Fig. 8 with schematic cross-sectional illustrate in opening, the 3rd embodiment of the nebulizer proposed 1 of starting state.The 3rd embodiment major part is corresponding to the second embodiment, but connecting device 24 also is not so good as the planar side covered from the annular flange flange by inner body 41 in the second embodiment but is engaged in storage 3 and (utilizes particularly finger piece 33 and Connection Element 34) from contrary planar side.
Fig. 9 is to illustrate source in the 4th embodiment of the nebulizer proposed 1 of transmission location or lock-out state.
In the 4th embodiment, cover 10 other Function Coupling with nebulizer 1 of opening and/or close preferably not.
Figure 10 illustrates the nebulizer 1 in unlocked state with schematic cross-sectional.
In the 4th embodiment, nebulizer 1 has can axially movable toward each other two preferred outer enclosure parts, upper case part 47 and lower case part 48 particularly.Particularly, as shown in Figure 10, the preferably biasing away from each other by a plurality of spring elements 49 of casing part 47,48, make in non-locking and non-compressed state, and upper case part 47 axially raises with respect to lower case part 48.
Two casing parts 47,48 can be with together with the power of spring element 49 moves axially on the contrary.In the axial compression state, breech locked is together particularly for two casing parts 47,48.This breech lock can discharge by activating relieving mechanism 46.
From the transmission position, after release, by spring element 49, automatic axial moves away from lower case part 48 to upper case part 47.This causes the actuating of delivery apparatus 5 away from motion or lifter motion, that is to say the increase of pump chambers 6 and the suction of surrounding air.In addition, the spring 14 be associated with delivery apparatus 5 (its retractable sack 7 particularly) is whereby by axial tightening or compression.Therefore spring element 21 has the spring force that is greater than spring 14.
In addition, above-mentioned axially-movable or lifter motion cause that the actuation element 41 be associated with spring 14 axially raises or shifts out.
In addition, axially lifter motion causes that storage 3 moves axially and separates with connecting device 24 (not illustrating in detail).
Then, user (not shown) must be with together with the power of spring element 49 manually axially promotes two casing parts 47,48 on the contrary.During this axially-movable and/or formerly, during lifter motion, storage 3 is container 4 ground rotations one by one further.The further rotation of storage 3 or reach are preferably carried out by the slidably control of transmitting device 23 etc. again.Along with process continues, the container 4 turned in delivery apparatus then is opened and preferably is connected to conveyer device via connecting device 24 (not shown) herein again.
Figure 11 is illustrated in the starting state that promotes the nebulizer 1 of gained after together, wherein casing part 47,48 breech locks or lock together and actuation element 21 axially outstanding.Preferably, only when reaching this state or only after being opened, cover 10 just likely activates on actuation element 21 the sending and atomization from the preparation of the dosage through opening container 4 with permission.
By activating (particularly, axially be pressed into) actuation element 21, the blocking-up of retracting spring 14, make spring 14 axially to relax and to activate whereby delivery apparatus 5, make particularly air pressurized contained in pump chambers 6, make this air via attached container 4, carry and in wanted mode via mouthpiece 8 delivery formulations 2.
The 4th embodiment also allows the very operation of simple, intuitive.Prevent maloperation by suitable blocking-up member particularly.
Figure 12 to Figure 14 illustrates the 5th embodiment of the nebulizer proposed 1 of the various states in the they's state corresponding to shown in Fig. 9 to Figure 11.
The 5th embodiment and the 4th embodiment difference in essence be, container 4 or insert 28 open, pierce through and/or the mobile and/or direction of aiming at respect to the axis 12 of storage 3 or container 4 or loop configurations at least in fact axially or extend in parallel but not radially extend.In shown embodiment, mouthpiece 8 therefore configure or be formed on storage 3 tops at nebulizer 1 or shell 13 (under this situation, the upper case part 47 particularly) side on, simultaneously mouthpiece 8 in fact with the planar side of nebulizer 1 ground or vertically outstanding or stretch out that meets at right angles.
In the 5th embodiment, from the transmission location shown in Figure 12, at first, cover 10 and must open, and, in shown embodiment, they preferably can be around axis 12 rotations of tangential extension.Only approach relieving mechanism 46 as cover 10 Shi Caike that have been opened.Other aspect programs are identical with the program of the 4th embodiment.
Figure 15 illustrates the 6th embodiment of the nebulizer proposed 1 in transmission location with schematic cross-sectional.The 6th embodiment is similar to the 4th embodiment on principle particularly.Yet different from previous embodiment, the 6th embodiment does not have delivery apparatus 5.More suitably, it is passive type nebulizer 1.
In transmission location, axially movable two casing parts 47 and 48 are particularly by least one snap fit hook 50 etc. and breech lock or lock together away from each other.After this at least one snap fit hook 50 can preferably be engaged on the annular shoulder 51 on another casing part 47,48 etc., so that the chain fixing be formed in latched position in the axial direction between two casing parts 47,48 connects.
In the 4th embodiment, preferably provide a plurality of spring elements 49.In the 6th embodiment, the only central spring element 49 formed by the central spiral spring particularly preferably is provided, this central spring element 49 supports two casing parts 47 and opens in 48 minutes.As shown in Figure 16, under this situation, when activating central relieving mechanism 46 by axial compressive force particularly, at least one snap fit hook 50 grades are jumped out, that is to say, do not form the breech lock of two casing parts 47 and 48, make two casing parts 47 and 48 to move axially away from each other.As the result of this lifter motion, storage 3 preferably further rotates a container 4.Away from motion or axially-movable, due to the spring force of spring element 49, automatically occur.This axially-movable preferably is converted to again desired, the progressively rotational motion of storage 3 by gear or tooth, rail plate etc. (not shown).Preferably, the ball point pen mechanism of previously mentioning also can start to work herein.Simultaneously, as the result away from motion, the container 4 that the Connection Element 34 of connecting device 24 has been emptied between can a comfortable upper delivery period separates.
Then, with the power of spring element 49 on the contrary by together with two casing parts, 47,48 Manual press.In this way, spring element 49 is again strained and is connected or open next container 4 by connecting device 24 (its Connection Element 34 particularly).Finally, as shown in Figure 15, at least one snap fit hook 50 is again automatically locking two casing parts 47 and 48 together in promoting end position together.
Now can be sucked.In the 6th embodiment, as the Connection Element 34 in Figure 17 is schematically indicated by arrow 54, by breathing, user or sufferer (not shown) produce that entrance 52 via Connection Element 34 is delivered in the container 4 of opening or piercing through and are passed to the air-flow of mouthpiece 8 via the outlet 53 of Connection Element 34 with together with preparation 2 from container 4.
In the 6th embodiment, the container 4 used is preferably also axially opened or pierces through.For instance, indicated in details as shown in Figure 18 particularly, storage 3 is configured to comprise the foaming ring (not shown) of a plurality of foaming bags herein, or is configured to particularly have a plurality of preferred axes for taking in foaming ring (not shown) or foaming bag loop bracket 55 to the dimple 56 of opening.In shown embodiment, particularly, storage 3 directly forms or is fixedly attached to particularly lower case part 48 by lower case part 48.
The 6th embodiment preferably includes a blocking vessel 57, and it blocks further and activates after all containers 4 have been used or have been emptied, and blocks particularly further opening or the motion of casing part 47 and 48 of nebulizer 1.Blocking vessel 57 for example forms the hook on storage 3, associated inner body 41 or loop bracket 55, and for example be engaged in the bearing 58 formed on upper case part 47 when arriving blocking position, make two casing parts 47 and 48 can not move axially again separately.This blocking-up is also preferably irreversible.Figure 18 illustrates in the position that casing part still is separated from each other in it.
Be similar to other embodiments, the 6th embodiment preferably includes an enumerator 59, in shown embodiment, this enumerator 59 preferably include one on storage 3 (particularly, on the outer periphery of storage 3 or lower case part 48) corresponding scale 60, and one in shell 13 the corresponding window 61 of (particularly, in upper case part 47).The relative rotation position of storage 3 is corresponding to being used or the number of operational container 4 still.Therefore, scale 60 can be indicated the still number of the available or container 4 that has been used.Figure 19 illustrates enumerator 59 to excise a part of side view.
Figure 20 illustrates the nebulizer 1 in unlocked state (that is to say, in the axial rising situation of upper case part 47) with the view corresponding to Figure 19.In this position, storage 3 has preferably been moved axially and has made scale 60 invisible with respect to window 61.Instead, preferably how a symbol (arrow etc.) particularly operates on it to illustrate to user through indication, that is to say optionally by two casing parts 47 and 48 are pressed together.On this aspect, enumerator not only is used for counting but also having the operation of the nebulizer 1 of another function auxiliary block post proposition.
As indicated in Figure 15 and Figure 16, according to the nebulizer 1 of the 6th embodiment, can there is central authorities or the axial dimple 62 in shell 13 or upper case part 47.This dimple 62 can be used for additional functionality or device.
Figure 21 illustrates the alternate embodiment of the nebulizer 1 that has clock 63 or have time measurement device.Clock 63 be preferably mounted in dimple be incorporated in addition nebulizer 1 or its shell 13 in.Making that clock 63 is constructed particularly can be sent preferred optics, acoustics and/or vibration signal to remind user to use nebulizer 1.
Figure 22 illustrates another alternate embodiment had for the nebulizer 1 of the sealed chamber of (not shown) such as medicaments or other containers.Particularly, dimple 62 structure to hold medicament etc. and can for example seal by lid 64 or other closures.
Figure 23 illustrates the 8th embodiment in the nebulizer proposed 1 of transmission location (that is to say, close in situation at cover 10) with schematic cross-sectional.The 8th embodiment is the passive type nebulizer 1 that is similar to the nebulizer 1 in the 7th embodiment.Yet, by rotation or rotary cover 10, open and close and activate on nebulizer 1 principle corresponding to the first to the 3rd embodiment.
In the 8th embodiment, storage 3 and connecting device 24 are constructed as the 7th embodiment in essence.Connecting device 24 or its Connection Element 34 are axially movable by by means of gear (not illustrating in detail), opening and close cover 10.In transmission location, connecting device 24 or its Connection Element 34 move axially away from storage 3.
By opening cover 10 (rotation preferably approximately reaches 180 °), at first move forward or further rotate storage 3, and, along with axially-movable continues, by connecting device 24, piercing through by Connection Element 34 particularly or other attached next container 4 of opening.Figure 24 illustrates this starting state with schematic cross-sectional.
When user or sufferer (not shown) while being breathed to suck, generation is the air flow by container 4 or storage chamber 31 (such as the bag etc. that foams) via Connection Element 34, and in this way via connecting contained preparation 2 in mouthpiece 8 discharges delivery container 4.
For permitting simple and cheap structure, entrance 52 and export 53 and preferably form by common assembly, form by single-piece Connection Element 34 particularly.In addition, Connection Element 34 preferably also has an exit passageway 65 that is adjacent to outlet 53 and broadens with funnel shaped or other suitable methods particularly.Therefore, do not need the mouthpiece 8 on conventional sense or be generally used for extension of inhaler etc.More suitably, the correspondence that has shell aperture and (if necessary) shell 13 is shaped be enough in case be formed for user or sufferer (not shown) closely, joint space-efficient mouthpiece 8.
Figure 25 illustrates a schematic diagram, and its explanation is according to the transmitting device 23 of the nebulizer 1 of the 8th embodiment.Particularly, tooth 44 is (particularly movingly for axial tooth 43 on the storage side and the axially-displaceable on shell side, together with connecting device 24) cooperate, in order to reach storage 3 desired progressively reach or the further rotation of container 4 one by one, wherein to coordinate tooth 44 to be associated with opening of cover 10 with respect to each axially-movable of tooth 43.Particularly, previously mentioned ball point pen principle starts to work again.
Yet, other structure solutions are also possible, so that the motion (particularly, certainly opening and/or close derivative rotatablely moving and/or axially-movable) of opening and/or closing that has concurrently by cover 10 is reached the desired progressively reach of storage 3 or further rotates.
Form contrast with the 7th embodiment, in the 8th embodiment, enumerator 59 preferred disposition are on the planar side or axial side of nebulizer 1, and window 61 is formed in cover 10 and reaches in shell 13 particularly, make preferably the current state of read-out counter all the time, even when closing cover 10.
Equally in the 8th embodiment, storage 3 also preferably possesses a loop bracket 55 for fixing foaming configuration (foaming ring etc.) particularly.Yet, basically can use the storage 3 of any wanted type herein, even there is particularly the storage 3 of the insert 28 that is used to form container 4.
Due to needed only for opening cover 10 in order to start nebulizer 1 (that is to say, for atomization or suck ready), therefore the 8th embodiment allows especially shirtsleeve operation.Even, after atomization or sucking, also do not need other operation bidirectionals.More suitably, only be necessary to close nebulizer 1 or cover 10.When closing cover 10 the time, connecting device 24 or its Connection Element 34 move axially away from storage 3 or the container 4 opened recently, make and recover the transmission location shown in Figure 23.
Figure 26 illustrates the schematic basic representation of height of concept of the 9th embodiment of proposed nebulizer 1.The 9th embodiment relates to and has the active nebulizer 1 that the delivery apparatus 5 of preferred disposition in the loop configurations of storage 3 or container 4 and energy storage or spring store, container 4 in Figure 26 only by taking in chamber 29 indications.
In the 9th embodiment, delivery apparatus 5 also preferable configuration is pump and possesses particularly retractable sack 7, retractable sack 7 for pumping in the radial direction on delivery apparatus 5 preferably movably, extensible and scalable or compressible specifically.After spring storage or spring 14 preferably are configured in retractable sack 7 on this pumping direction, be configured in particularly on the side away from connecting device 24.
Figure 26 is illustrated in the spring in bias state in retractable sack 7 extension situations and stores or spring 14.Under this state, by delivery apparatus 5 or retractable sack 7, be absorbed into surrounding air.
Utilize contrary radial motion, next container 4 or insert 28 can be pierced and radially outward promote particularly to open its sealing out of the ordinary.During this radial motion, spring 24 keeps compression or tension and retractable sack 7 to keep extending.Therefore, reach the starting state of nebulizer 1.
Preferably, utilize the actuating of actuation element (not shown), spring 14 is through discharging in order to compress retractable sack 7, that is to say in order to actuated pump, make compressed delivery media (that is to say air) be forced through insert 28 to send or discharge or atomization or remove the preparation 2 of coalescent each dosage and produce will spraying of preparation 2.
The part of radial motion preferably, also with so that storage 3 points to or moves to next container 4, that is to say to activate transmitting device 23.
In the 9th embodiment, transmitting device 23 is preferably particularly via pinion 66 inner engagement on storage 3, and this pinion 66 preferably is engaged in the internal tooth 67 of storage 3.
Have to be noted that connecting device 24 and pump 5 are preferably formed a unit or interconnection.
In the 9th embodiment, container 4/ is taken in chamber 29 formation and is arranged on the preferred independent part on preferred class ring carriage 55 with fit form and/or rigid manner particularly.Take in chamber 29 or container 4 preferably by distinctly seal and/or preferably at least seal separately or individually (not shown in Figure 26 and Figure 27) on its exterior periphery periphery.
Figure 28 with similarly very schematically basic representation the tenth embodiment of the nebulizer 1 proposed is shown.The tenth embodiment relates to the 9th embodiment and is similar to particularly the 9th embodiment, and configuration and/or the function aspects at delivery apparatus 5 and connecting device 24 is similar to the 9th embodiment best, and does not therefore need the explanation to these.
Figure 29 illustrates with Figure 28 and forms the nebulizer according to the tenth embodiment 1 that contrast has shell 13 and preferred rotatable or rotatable cover 10 with schematic cross-sectional.
The tenth embodiment allows (particularly) to cover 10 rotation or rotational motion and is converted to linearity and/or radial motion in order to activate delivery apparatus 5 and/or connecting device 24, best so that mobile link element 34.Particularly, to slide and/or automatically gear-drivenly couple or control.
In shown embodiment, nebulizer 1 has at least one control element 68, and it is constructed in dish mode (comparing with Figure 28) particularly.Control element 68 preferably is coupled to rotationally cover 10 (in shown embodiments, via the axial engagement 69 as indicated in Figure 29) or for example forms by cover element 10.
Especially preferably, control element 68 forms a rail plate or some rail plates, so as with wanted or the mode of necessity activates (particularly) delivery apparatus 5 and connecting device 24 or its Connection Element 34.Yet, also may use in theory independent control element 68, rail plate and/or other gear drives to connect, to control and to activate on the one hand delivery apparatus 5 and to control on the other hand and activate connecting device 24 or its Connection Element 34, and/or the different sections for moving.
In shown embodiment, provide the first control cam or rail plate 70 for connecting device 24 or pass through delivery apparatus 5 and/or preferred linearity or the radial motion of the slide plate 79 that connecting device 24 forms.For this purpose, particularly, the first engaged element 71 is engaged in the first rail plate 70.Preferably, the first engaged element 71 is rigidly connected to connecting device 24 or its Connection Element 34 directly or indirectly.
The first rail plate 70 is shown in Figure 28 is opening.Yet it also can be particularly dimple as shown in Figure 29, groove etc.
The path of the first rail plate 70 is determined that gear drive couples or determined also can be along circumference and/or the linear movement of radially extending and the dependence of rotational motion.In shown embodiment, the first rail plate 70 comprises the first section 72 extended on circumference particularly, the second preferred linear segments 73 of connection and/or the second section 73 with radial component, and/or the 3rd section 74 again extended on circumference particularly.
Therefore, between cover 10 period of energization, that is to say, during cover 10 rotates the position shown in Figure 28 and Figure 29 (closed position or transmission location), at first, during the first section 72, do not have linearity or the radial motion of connecting device 24 or slide plate 79.In shown embodiment, slide plate 79 or connecting device 24 only occur further along linearity or the radial motion of the second section 73, make Connection Element 34 contact with next container 4, be engaged on particularly in next container 4 or next insert 28, being created in best delivery apparatus 5 or Connection Element 34 is communicated with the fluid between storage chamber 31, and optionally by the insert 28 that radially moves forward, move it by opening 30 particularly, in order to open opening 30.Nebulizer 1 presents enable position.
At the self closing status transition to during starting state, delivery apparatus 5 or spring store or spring 14 preferably in tension.Therefore, actuation element 21 now can activated, make particularly by making lock arm 20 deflections and retracting spring 14 or retractable sack 7 compressor pump chamber 6 and delivery formulation 2 whereby, as its result, preparation 2 is discharged or is sent by delivery media and atomization particularly in wanted mode, as previously explained.
In shown embodiment, cover 10 or control element 68 preferably be used for activating delivery apparatus 5 simultaneously, in order to bias spring, store or spring 14 particularly.For this purpose, control element 68 comprises the second control cam or rail plate 75, the second engaged element 76 and this second control cam or rail plate 75 cooperations, particularly, in shown embodiment, second control cam or rail plate 75 and delivery apparatus 5 spring stores or spring 14 (particularly, spring 14 radially or linear removable bearing 77) be associated, or directly or indirectly firmly be connected to delivery apparatus 5 or spring stores or spring 14.
Especially preferably, slidably or with on delivery apparatus 5 or the mode of the slide plate on slide plate 79 guide bearing 77, slide plate 79 again with the mode of slide plate in the direction of motion (under this situation, radial direction) on slidably, and fixing or carrying connecting device 24 or its Connection Element 34 particularly.
Figure 29 illustrates the spring 14 (under this situation, compressed state) in offset position.Bearing 77 is by means of lock arm 20 at least and be immobilizated in offset position.In shown embodiment, the second rail plate 75 preferable configuration so that in closed position or transmission location, spring store or spring 14 fastening non-desired lax to prevent by the shoulder 78 of the radial motion in this position blocking-up the second engagement 76 particularly.
When actuation element 21 activated, lock arm 20 does not complete to extrinsic deflection or locking mesh, and lax spring stores or spring 14 or triggering delivery apparatus 5.Then, spring 14 is in previous described mode, in shown embodiment with linear mode or compressing in the radial direction retractable sack 7 or pump chambers 6.Therefore, as explained referring to other embodiments, then send and the hang oneself container 4 that connects or the preparation 2 (not shown in Figure 28 and Figure 29) of the insert 28 through connecting of atomization particularly.
Between relaxation period, the second engaged element 76 moves (and optionally exceeding) towards nebulizer 1 or control element 68 center or towards the pivot center of cover 10 particularly.The second rail plate 75 is through correspondingly freely cutting to allow this motion.In shown embodiment, the radial segment 80 along the second rail plate 75 on this motion essence is extended.
In shown embodiment, particularly cover 10 close or travelling backwards during, control element 68 returns or spring stores or spring 14 again in tension.
Position travelling backwards in control element 68 self-starting states or (preferably with respect to the position in Figure 28 and Figure 29, rotate 90 ° to 180 °) while returning, maintenance section 81 by the second rail plate 75 stops bearing 77 via the second engaged element 76 on a certain section of the contrary radial motion of slide plate 79 or the first engaged element 71, make in this section of motion, spring stores or spring 14 is biased again and retractable sack 7 extends again, particularly until by means of lock arm 29, breech lock occurs.Between this moving period, Connection Element 34 is preferably recalled at least in part from attached container 4 or attached insert 28 simultaneously.
During further linearity or radial motion, delivery apparatus 5, connecting device 24, Connection Element 34 and slide plate 79 together with spring 14 travelling backwards of biasing to the original position shown in Figure 28 and Figure 29.
In shown embodiment, above-mentioned motion sequence is particularly by closing cover 10 and making control element 68 return to carry out with closing to be associated.
Figure 29 illustrates preferred annular storage 3 with pure schematic form again.In conjunction with this figure, can be with reference to particularly about the annotation of other embodiments.
During the rotation of opening motion and/or closing movement or control element 68 of cover 10, in the tenth embodiment, not shown transmitting device 23 preferably can activated in order to make storage 3 move forward to next container 4.This couples etc. by means of corresponding or suitable gear drive particularly and completes.For instance, as explained before, can carry out moving axially of storage 3 for this purpose, move forward by means of execution such as preferred control cams 26 on shell side in a circumferential direction or particularly.Particularly or or, as using in other embodiments particularly the gear drive by means of screw thread to couple.
But the individual characteristics of indivedual embodiments and aspect be combination with one another also, as required or use in other structures of nebulizer, inhaler, dispensing device etc.
In the present invention, preferably should explain very widely term " nebulizer " in order to comprise other delivery apparatus, dispensing device etc., simultaneously preparation 2 or other media or fluid only need be when being required atomization and optionally can also multi-formly sending.
Hereinafter list some preferred composition and/or compositionss of preferred pharmaceutical formulation 2.As mentioned, it is in particular powder or liquid in broad sense.Especially preferably, preparation 2 contains following each material:
Hereinafter listed compound can himself or combination for apparatus of the present invention.Hereinafter in mentioned compound, W is pharmacological active substance and for example is selected from following material: β analogies (betamimetics), anticholinergic, corticosteroid, PDE4-inhibitor, LTD4-antagonist, EGFR-inhibitor, dopamine agonist, H1-antihistaminic, PAF-antagonist and PI3-inhibitors of kinases.In addition, dual or three recombinations of W can be through combination and for apparatus of the present invention.The combination of W for example may be:
-W means the combination of β analogies and anticholinergic agents, corticosteroid, PDE4-inhibitor, EGFR-inhibitor or LTD4-antagonist,
-W means the combination of anticholinergic agents and β analogies, corticosteroid, PDE4-inhibitor, EGFR-inhibitor or LTD4-antagonist,
-W means the combination of corticosteroid and PDE4-inhibitor, EGFR-inhibitor or LTD4-antagonist,
-W means the combination of PDE4-inhibitor and EGFR-inhibitor or LTD4-antagonist,
-W means the combination of EGFR-inhibitor and LTD4-antagonist.
Preferably, it as the compound of β analogies, is the compounds that are selected from following: albuterol, Ah's formoterol (arformoterol), bambuterol, bitolterol, broxaterol, carbuterol, clenbuterol, fenoterol, formoterol, hexoprenaline, ibuterol, neoisuprel, isoproterenol, levosalbutamol, Mabuterol, meluadrine, orciprenaline, orciprenaline, pirbuterol, procaterol, reproterol, rimiterol, ritodrine, Salmefamol, salmaterol, soterenol (soterenol), Suo Fenteluo (sulphonterol), terbutaline, tiaramide, special sieve (tolubuterol) of special infectious coryza, zinterol (zinterol), CHF-1035, HOKU-81, KUL-1248, and
3-(4-{6-[2-hydroxyl-2-(4-hydroxyl-3-hydroxymethyl-phenyl)-ethylamino]-hexyl oxygen base }-butyl)-benzyl-sulfonamide
5-[2-(5,6-diethyl-indane-2-base amino)-1-hydroxyl-ethyl]-8-hydroxyl-1H-quinoline-2-one-
4-hydroxyl-7-[2-{[2-{[3-(2-phenyl ethoxy) propyl group] sulfonyl } ethyl]-amino } ethyl]-2 (3H)-benzothiazolones
1-(the fluoro-4-hydroxy phenyl of 2-)-2-[4-(1-benzimidazolyl)-2-methyl-2-butyl amino] ethanol
1-[3-(4-methoxy-benzyl-amino)-4-hydroxy phenyl]-2-[4-(1-benzimidazolyl)-2-methyl-2-butyl amino] ethanol
1-[2H-5-hydroxyl-3-oxo-4H-1,4-benzoxazinyl-8-yl]-2-[3-(4-N, N-dimethylaminophenyl)-2-methyl-2-propyl amino] ethanol
1-[2H-5-hydroxyl-3-oxo-4H-1,4-benzoxazinyl-8-yl]-2-[3-(4-methoxyphenyl)-2-methyl-2-propyl amino] ethanol
1-[2H-5-hydroxyl-3-oxo-4H-1,4-benzoxazinyl-8-yl]-2-[3-(4-normal-butyl oxygen base phenyl)-2-methyl-2-propyl amino] ethanol
1-[2H-5-hydroxyl-3-oxo-4H-1,4-benzoxazinyl-8-yl]-2-{4-[3-(4-methoxyphenyl)-1,2,4-triazole-3-yl]-2-methyl-2-butyl amino } ethanol
5-hydroxyl-8-(1-hydroxyl-2-isopropylamino butyl)-2H-1,4-benzoxazinyl-3-(4H)-one
1-(the chloro-5-trifluoromethyl of 4-amino-3-)-2-tert-butyl group amino) ethanol
6-hydroxyl-8-{1-hydroxyl-2-[2-(4-methoxyl group-phenyl)-1,1-dimethyl-ethylamino]-ethyl }-4H-benzo [Isosorbide-5-Nitrae] oxazine-one
6-hydroxyl-8-{1-hydroxyl-2-[2-(4-phenoxy group-acetic acid ethyl ester)-1,1-dimethyl-ethylamino]-ethyl }-4H-benzo [Isosorbide-5-Nitrae] oxazine-3-ketone
6-hydroxyl-8-{1-hydroxyl-2-[2-(4-phenoxy group-acetic acid)-1,1-dimethyl-ethylamino]-ethyl }-4H-benzo [Isosorbide-5-Nitrae] oxazine-3-ketone
8-{2-[1,1-dimethyl-2-(2,4,6-trimethylphenyl)-ethylamino]-1-hydroxyl-ethyl }-6-hydroxyl-4H-benzo [Isosorbide-5-Nitrae] oxazine-3-ketone
6-hydroxyl-8-{1-hydroxyl-2-[2-(4-hydroxyl-phenyl)-1,1-dimethyl-ethylamino]-ethyl }-4H-benzo [Isosorbide-5-Nitrae] oxazine-3-ketone
6-hydroxyl-8-{1-hydroxyl-2-[2-(4-isopropyl-phenyl)-1,1-dimethyl-ethylamino]-ethyl }-4H-benzo [Isosorbide-5-Nitrae] oxazine-3-ketone
8-{2-[2-(4-ethyl-phenyl)-1,1-dimethyl-ethylamino]-1-hydroxyl-ethyl }-6-hydroxyl-4H-benzo [Isosorbide-5-Nitrae] oxazine-3-ketone
8-{2-[2-(4-ethyoxyl-phenyl)-1,1-dimethyl-ethylamino]-1-hydroxyl-ethyl }-6-hydroxyl-4H-benzo [Isosorbide-5-Nitrae] oxazine-3-ketone
4-(4-{2-[2-hydroxyl-2-(6-hydroxyl-3-oxo-3,4-dihydro-2H-benzo [Isosorbide-5-Nitrae] oxazine-8-yl)-ethylamino]-2-methyl-propyl group }-phenoxy group)-butanoic acid
8-{2-[2-(the fluoro-phenyl of 3,4-bis-)-1,1-dimethyl-ethylamino]-1-hydroxyl-ethyl }-6-hydroxyl-4H-benzo [Isosorbide-5-Nitrae] oxazine-3-ketone
1-(4-ethyoxyl-carbonylamino-3-cyano group-5-fluorophenyl)-2-(tert-butyl group amino) ethanol
2-hydroxyl-5-(1-hydroxyl-2-{2-[4-(2-hydroxyl-2-phenyl-ethylamino)-phenyl]-ethylamino }-ethyl)-benzaldehyde
N-[2-hydroxyl-5-(1-hydroxyl-2-{2-[4-(2-hydroxyl-2-phenyl-ethylamino)-phenyl]-ethylamino }-ethyl)-phenyl]-Methanamide
8-hydroxyl-5-(1-hydroxyl-2-{2-[4-(6-methoxyl group-biphenyl-3-base amino)-phenyl]-ethylamino }-ethyl)-the 1H-quinoline-2-one-
8-hydroxyl-5-[1-hydroxyl-2-(6-phenethyl amino-hexyl amino)-ethyl]-the 1H-quinoline-2-one-
5-[2-(2-{4-[4-(2-amino-2-methyl-propoxyl group)-phenyl amino]-phenyl }-ethylamino)-1-hydroxyl-ethyl]-8-hydroxyl-1H-quinoline-2-one-
[3-(4-{6-[2-hydroxyl-2-(4-hydroxyl-3-hydroxymethyl-phenyl)-ethylamino]-hexyl oxygen base }-butyl)-5-methyl-phenyl]-urea
4-(2-{6-[2-(the chloro-benzyloxy of 2,6-bis-)-ethyoxyl]-hexyl amino }-1-hydroxyl-ethyl)-2-hydroxymethyl-phenol
3-(4-{6-[2-hydroxyl-2-(4-hydroxyl-3-hydroxymethyl-phenyl)-ethylamino]-hexyl oxygen base }-butyl)-benzsulfamide
3-(3-{7-[2-hydroxyl-2-(4-hydroxyl-3-hydroxymethyl-phenyl)-ethylamino]-heptyl oxygen base }-propyl group)-benzsulfamide
4-(2-{6-[4-(3-Pentamethylene. sulfonyl-phenyl)-butoxy]-hexyl amino }-1-hydroxyl-ethyl)-2-hydroxymethyl-phenol
N-diamantane (obsolete)-2-base-2-(3-{2-[2-hydroxyl-2-(4-hydroxyl-3-hydroxymethyl-phenyl)-ethylamino]-propyl group }-phenyl)-acetamide,
Optional with the form of its racemic modification, enantiomer or diastereomer or optionally with the acceptable acid-addition salts of its pharmacology, solvate or hydrate forms.According to the present invention, the acid-addition salts of β analogies is preferably selected from following each salt: hydrochlorate, hydrobromate, hydriodate, sulfate, phosphate, methane sulfonates, nitrate, maleate, acetate, citrate, fumarate, tartrate, oxalates, succinate, benzoate and tosilate.
Spendable preferred anticholinergic preferably is selected from: tiotropium (Tiotropium) salt is preferably bromide salt; Oxygen holder ammonium (Oxitropium) salt, be preferably bromide salt; Fluorine holder ammonium (Flutropium) salt, be preferably bromide salt; Ipratropium (Ipratropium) salt, be preferably bromide salt; GLYCOPYRRONIUM (Glycopyrronium) salt, be preferably bromide salt; Trospium cation (Trospium) salt, be preferably chloride salt, i.e. tolterodine (Tolterodin).In salt referred to above, pharmacologically active is partly cation.Anion can be preferably chloride ion, bromide ion, iodide ion, sulfate radical, phosphate radical, Loprazolam root, nitrate anion, maleate, acetate, citrate, fumaric acid radical, tartrate anion, oxalate, amber acid radical, benzoate anion or p-methyl benzenesulfonic acid root, simultaneously chloride ion, bromide ion thing, iodide ion, sulfate radical, Loprazolam root or the preferred counter ion counterionsl gegenions of p-methyl benzenesulfonic acid root.With regard to all salt, chloride, bromide, iodide and methane sulfonates are especially preferred.
Other preferred anticholinergic are the salt that is selected from formula AC-1,
X wherein
-indication has the anion of single negative charge, preferably be selected from the anion in following: fluorion, chloride ion, bromide ion, iodide ion, sulfate radical, phosphate radical, the Loprazolam root, nitrate anion, maleate, acetate, citrate, fumaric acid radical, tartrate anion, oxalate, amber acid radical, benzoate anion and p-methyl benzenesulfonic acid root, be preferably the anion with single negative charge, especially be preferably selected from following anion: fluorion, chloride ion, bromide ion, Loprazolam root and p-methyl benzenesulfonic acid root, especially be preferably bromide ion, optionally be racemic isomer, the form of enantiomer or hydrate.The person of being even more important is those medicine combinations of the enantiomer that contains formula AC-1-en
X wherein
-can there is implication mentioned above.Other preferred anticholinergic are the salt that is selected from formula AC-2
Wherein R means methyl or ethyl, and wherein X-can have implication mentioned above.
In substituting embodiment, the form that formula AC-2 compound can also free alkali AC-2-alkali exists.
AC-2-alkali
Other concrete compounds are:
2,2-diphenyl-propionic acid tropine alcohol ester Methobromide,
2,2-diphenyl-propionic acid Di(2-thienyl)glycolic acid scopine ester. Methobromide,
2-is fluoro-2,2-diphenyl acetic acid Di(2-thienyl)glycolic acid scopine ester. Methobromide,
2-is fluoro-2,2-diphenyl acetic acid tropine alcohol ester Methobromide,
3,3 ', 4,4 '-tetrafluoro diphenylglycollic acid tropine alcohol ester Methobromide,
3,3 ', 4,4 '-tetrafluoro diphenylglycollic acid Di(2-thienyl)glycolic acid scopine ester. Methobromide,
4,4 '-difluorodiphenyl glycolic tropine alcohol ester Methobromide,
4,4 '-difluorodiphenyl glycolic Di(2-thienyl)glycolic acid scopine ester. Methobromide,
3,3 '-difluorodiphenyl glycolic tropine alcohol ester Methobromide,
3,3 '-difluorodiphenyl glycolic Di(2-thienyl)glycolic acid scopine ester. Methobromide,
9-hydroxyl-fluorenes-9-carboxylic acid tropine alcohol ester Methobromide,
The fluoro-fluorenes of 9--9-carboxylic acid tropine alcohol ester Methobromide,
9-hydroxyl-fluorenes-9-carboxylic acid Di(2-thienyl)glycolic acid scopine ester. Methobromide,
The fluoro-fluorenes of 9--9-carboxylic acid Di(2-thienyl)glycolic acid scopine ester. Methobromide,
9-methyl-fluorenes-9-carboxylic acid tropine alcohol ester Methobromide,
9-methyl-fluorenes-9-carboxylic acid Di(2-thienyl)glycolic acid scopine ester. Methobromide,
Diphenylglycollic acid cyclopropyl hyoscyamine ester Methobromide,
2,2-diphenyl-propionic acid cyclopropyl hyoscyamine ester Methobromide,
9-hydroxyl-xanthene-9-carboxylic acid cyclopropyl hyoscyamine ester Methobromide,
9-methyl-fluorenes-9-carboxylic acid cyclopropyl hyoscyamine ester Methobromide,
9-methyl-xanthene-9-carboxylic acid cyclopropyl hyoscyamine ester Methobromide,
9-hydroxyl-fluorenes-9-carboxylic acid cyclopropyl hyoscyamine ester Methobromide,
4,4 '-difluorodiphenyl glycolic cyclopropyl hyoscyamine methyl ester Methobromide,
9-hydroxyl-xanthene-9-carboxylic acid tropine alcohol ester Methobromide,
9-hydroxyl-xanthene-9-carboxylic acid Di(2-thienyl)glycolic acid scopine ester. Methobromide,
9-methyl-xanthene-9-carboxylic acid tropine alcohol ester Methobromide,
9-methyl-xanthene-9-carboxylic acid Di(2-thienyl)glycolic acid scopine ester. Methobromide,
9-ethyl-xanthene-9-carboxylic acid tropine alcohol ester Methobromide,
9-difluoromethyl-xanthene-9-carboxylic acid tropine alcohol ester Methobromide,
9-hydroxymethyl-xanthene-9-carboxylic acid Di(2-thienyl)glycolic acid scopine ester. Methobromide.
Compound mentioned above also can be used as salt and uses within the scope of the invention, and wherein, except Methobromide, these salt can be used methyl-X, and wherein X can have above the implication given for X-.
As corticosteroid, preferably use the compound be selected from following:
Beclometasone, betamethasone, budesonide, butixocort, ciclesonide, deflazacort, dexamethasone, Ai Puruinuo, flunisolide, fluticasone, loteprednol, mometasone, prednisolone, prednisone, rofleponide, triamcinolone, RPR-106541, NS-126, ST-26 reach
The fluoro-17-[(2-furyl carbonyl of 6,9-bis-) oxygen base]-11-hydroxyl-16-methyl-3-oxo-androstane-Isosorbide-5-Nitrae-diene-17-thiocarbonic acid (S)-methyl fluoride ester
The fluoro-11-hydroxyl of 6,9-bis--16-methyl-3-oxo-17-propionyloxy-androstane-Isosorbide-5-Nitrae-diene-17-thiocarbonic acid (S)-(2-oxo-tetrahydrochysene-furan-3S-yl) ester
6 α, 9 alpha-difluoro-11 betas-hydroxy-16 alpha--methyl-3-oxo-17 α-(2,2,3,3-tetramethyl cyclopropyl carbonyl) oxygen base-androstane-Isosorbide-5-Nitrae-diene-17 β-carboxylic acid cyano methyl ester
It optionally is racemic form, as enantiomer, diastereomer, or is optionally the form of the upper acceptable salt of pharmacology and derivant, solvate and/or hydrate.Corticosteroid comprises any salt or derivant, hydrate or the solvate that may exist.Possible salt and the example of derivant are alkali metal salt (for example sodium salt or potassium salt), sulfonic benzoic acid salt, phosphate, nicotimine hydrochlorate, acetate, dichloroacetate, propionate, dihydric phosphate, palmitate, pivalate or furoate.
Spendable PDE4-inhibitor preferably is selected from the compound among following material: enprofylline, theophylline, roflumilast, Ai Ruifu (cilomilast), TOEFL department special (Tofimilast), pumafentrine, Li Ruisite (Lirimilast), arofylline, if Ah 's agate, D4418, Bay-198004, BY343, CP-325366, D-4396 (Sch-351591), AWD-12-281 (GW-842470), NCS-613, CDP-840, D-4418, PD-168787, T-440, T-2585, V-11294A, C1-1018, CDC-801, CDC-3052, D-22888, YM-58997, Z-15370 reaches
N-(the chloro-1-oxo-pyridin-4-yl of 3,5-bis-)-4-difluoro-methoxy-3-cyclo propyl methoxy Benzoylamide,
(-) p-[(4aR
*, 10bS
*)-9-ethyoxyl-1,2,3,4,4a, 10b-six hydrogen-8-methoxyl group-2-methyl benzo [s] [1,6] benzodiazine-6-yl]-N, N-diisopropyl Benzoylamide
(R)-(+)-1-(4-benzyl bromide)-4-[(3-cyclopentyloxy)-4-methoxyphenyl]-2-Pyrrolidone
3-(cyclopentyloxy-4-methoxyphenyl)-1-(4-N '-[N-2-cyano group-S-methyl-isothiourea group] benzyl)-2-Pyrrolidone
Along [4-cyano group-4-(3-cyclopentyloxy-4-methoxyphenyl) cyclohexane extraction-1-carboxylic acid]
2-carbomethoxy-4-cyano group-4-(3-cyclo propyl methoxy-4-difluoro-methoxy phenyl) hexamethylene-1-ketone
Along [4-cyano group-4-(3-cyclo propyl methoxy-4-difluoro-methoxy phenyl) hexamethylene-1-alcohol]
(R)-(+)-ethyl [4-(3-cyclopentyloxy-4-methoxyphenyl) pyrrolidine-2-subunit] acetas
(S)-(-)-ethyl [4-(3-cyclopentyloxy-4-methoxyphenyl) pyrrolidine-2-subunit] acetas
9-cyclopenta-5,6-dihydro-7-ethyl-3-(2-thienyl)-9H-pyrazolo [3,4-c]-1,2,4-triazol [4,3-a] pyridine
9-cyclopenta-5,6-dihydro-7-ethyl-3-(tert-butyl group)-9H-pyrazolo [3,4-c]-1,2,4-triazol [4,3-a] pyridine,
The optional form with its racemic modification, enantiomer or diastereomer, or optionally with the acceptable acid-addition salts of its pharmacology, solvate and/or hydrate forms.According to the present invention, the acid-addition salts of PDE4-inhibitor is preferably freely following each salt of choosing: hydrochlorate, hydrobromate, hydriodate, sulfate, phosphate, nitrate, maleate, acetate, citrate, fumarate, tartrate, oxalates, succinate, benzoate and tosilate.
The LTD4-antagonist used preferably is selected from the compound in following material: montelukast, pranlukast, zafirlukast, MCC-847 (ZD-3523), MN-001, MEN-91507 (LM-1507), VUF-5078, VUF-K-8707, L-733321 reach
1-(((R)-(3-(2-(the fluoro-2-quinolyl of 6,7-bis-) vinyl) phenyl)-3-(2-(2-hydroxyl-2-propyl group) phenyl)-sulfenyl)-methyl-cyclopropane-acetic acid
(((((2-(2 for 3-in 1 (R)-3 for 1-, the 3-dichloro-thiophene is [3,2-b] pyridine-5-yl also)-(E)-vinyl) phenyl)-3-(2-(1-hydroxyl-1-methyl-ethyl) phenyl) propyl group) sulfenyl) methyl) cyclopropane-acetic acid
[2-[[2-(the 4-tert-butyl group-2-thiazolyl)-5-benzofuranyl] oxygen ylmethyl] phenyl]-acetic acid
The optional form with its racemic modification, enantiomer or diastereomer, or optional form, solvate and/or hydrate forms with the acceptable acid-addition salts of its pharmacology.Acid-addition salts according to the present invention is preferably and is selected from each salt: hydrochlorate, hydrobromate, hydriodate, sulfate, phosphate, nitrate, maleate, acetate, citrate, fumarate, tartrate, oxalates, succinate, benzoate and tosilate.The salt of LTD4-antagonist or derivant optionally form alkali metal salt (for example sodium salt or potassium salt), sulfonic benzoic acid salt, phosphate, nicotimine hydrochlorate, acetate, propionate, dihydric phosphate, palmitate, pivalate or furoate.
Spendable EGFR-inhibitor preferably is selected from the compound in following material: Cetuximab, trastuzumab, ABX-EGF, Mab ICR-62 reach
The chloro-4-fluorophenyl of 4-[(3-) amino]-6-{[4-(morpholine-4-yl)-1-oxo-2-butylene-1-yl] amino }-7-cyclo propyl methoxy-quinazoline
The chloro-4-fluorophenyl of 4-[(3-) amino]-6-{[4-(N, N-diethylamino)-1-oxo-2-butylene-1-yl] amino }-7-cyclo propyl methoxy-quinazoline
The chloro-4-fluorophenyl of 4-[(3-) amino]-6-{[4-(N, N-dimethylamino)-1-oxo-2-butylene-1-yl] amino }-7-cyclo propyl methoxy-quinazoline
4-[(R)-(1-phenyl-ethyl) amino]-6-{[4-(morpholine-4-yl)-1-oxo-2-butylene-1-yl] amino }-7-cyclopentyloxy-quinazoline
The fluoro-phenyl of the chloro-4-of 4-[(3-) amino]-6-{[4-((R)-6-methyl-2-oxo-morpholine-4-yl)-1-oxo-2-butylene-1-yl] amino }-7-cyclo propyl methoxy-quinazoline
The fluoro-phenyl of the chloro-4-of 4-[(3-) amino]-6-{[4-((R)-6-methyl-2-oxo-morpholine-4-yl)-1-oxo-2-butylene-1-yl] amino }-7-[(S)-(oxolane-3-yl) oxygen base]-quinazoline
The fluoro-phenyl of the chloro-4-of 4-[(3-) amino]-6-{[4-((R)-2-methoxy-6-oxo-morpholine-4-yl)-1-oxo-2-butylene-1-yl] amino }-7-cyclo propyl methoxy-quinazoline
The fluoro-phenyl of the chloro-4-of 4-[(3-) amino]-6-[2-((S)-6-methyl-2-oxo-morpholine-4-yl)-ethyoxyl]-7-methoxyl group-quinazoline
The chloro-4-fluorophenyl of 4-[(3-) amino]-6-(4-[N-(2-methoxyl group-ethyl)-N-methyl-amino]-1-oxo-2-butylene-1-yl } amino)-7-cyclo propyl methoxy-quinazoline
The chloro-4-fluorophenyl of 4-[(3-) amino]-6-{[4-(N, N-dimethylamino)-1-oxo-2-butylene-1-yl] amino }-7-cyclopentyloxy-quinazoline
4-[(R)-(1-phenyl-ethyl) amino]-6-{[4-(N, N-is two-(2-methoxyl group-ethyl)-amino)-1-oxo-2-butylene-1-yl] amino }-7-cyclo propyl methoxy-quinazoline
4-[(R)-(1-phenyl-ethyl) amino]-6-(4-[N-(2-methoxyl group-ethyl)-N-ethyl-amino]-1-oxo-2-butylene-1-yl } amino)-7-cyclo propyl methoxy-quinazoline
4-[(R)-(1-phenyl-ethyl) amino]-6-(4-[N-(2-methoxyl group-ethyl)-N-methyl-amino]-1-oxo-2-butylene-1-yl } amino)-7-cyclo propyl methoxy-quinazoline
4-[(R)-(1-phenyl-ethyl) amino]-6-(4-[N-(tetrahydropyran-4-base)-N-methyl-amino]-1-oxo-2-butylene-1-yl } amino)-7-cyclo propyl methoxy-quinazoline
The chloro-4-fluorophenyl of 4-[(3-) amino]-6-{[4-(N, N-dimethylamino)-1-oxo-2-butylene-1-yl] amino }-7-((R)-oxolane-3-base oxygen base)-quinazoline
The chloro-4-fluorophenyl of 4-[(3-) amino]-6-{[4-(N, N-dimethylamino)-1-oxo-2-butylene-1-yl] amino }-7-((S)-oxolane-3-base oxygen base)-quinazoline
The chloro-4-fluorophenyl of 4-[(3-) amino]-6-{[4-[N-(2-methoxyl group-ethyl)-N-methyl-amino]-1-oxo-2-butylene-1-yl } amino)-7-cyclopentyloxy-quinazoline
The chloro-4-fluorophenyl of 4-[(3-) amino]-6-{[4-(N-cyclopropyl-N-methyl-amino)-1-oxo-2-butylene-1-yl] amino }-7-cyclopentyloxy-quinazoline
The chloro-4-fluorophenyl of 4-[(3-) amino]-6-{[4-(N, N-dimethylamino)-1-oxo-2-butylene-1-yl] amino }-7-[(R)-(oxolane-2-yl) methoxyl group)-quinazoline
The chloro-4-fluorophenyl of 4-[(3-) amino]-6-{[4-(N, N-dimethylamino)-1-oxo-2-butylene-1-yl] amino }-7-[(S)-(oxolane-2-yl) methoxyl group)-quinazoline
4-[(3-acetenyl-phenyl) amino]-6,7-pair-(2-methoxyl group-ethyoxyl)-quinazoline
The chloro-4-fluorophenyl of 4-[(3-) amino]-7-[3-(morpholine-4-yl)-propyl group oxygen base]-6-[(vinyl-carbonyl) amino]-quinazoline
4-[(R)-(1-phenyl-ethyl) amino]-6-(4-hydroxyl-phenyl)-7H-pyrrolo-[2,3-d] pyrimidine
The chloro-4-fluorophenyl of 3-cyano group-4-[(3-) amino]-6-{[4-(N, N-dimethylamino)-1-oxo-2-butylene-1-yl] amino }-7-ethoxy yl-quinoline
The chloro-4-of 4-{[3-(the fluoro-benzyloxy of 3-)-phenyl] amino }-6-(5-{[(2-methane sulfonyl-ethyl) amino] methyl }-furan-2-yl) quinazoline
4-[(R)-(1-phenyl-ethyl) amino]-6-{[4-((R)-6-methyl-2-oxo-morpholine-4-yl)-1-oxo-2-butylene-1-yl] amino }-7-methoxyl group-quinazoline
The chloro-4-fluorophenyl of 4-[(3-) amino]-6-{[4-(morpholine-4-yl)-1-oxo-2-butylene-1-yl] amino }-7-[(oxolane-2-yl) methoxyl group]-quinazoline
The chloro-4-fluorophenyl of 4-[(3-) amino]-6-(4-[N, N-pair-(2-methoxyl group-ethyl)-amino]-1-oxo-2-butylene-1-yl } amino)-7-[(oxolane-2-yl) methoxyl group]-quinazoline
4-[(3-acetenyl-phenyl) amino]-6-{[4-(5,5-dimethyl-2-oxo-morpholine-4-yl)-1-oxo-2-butylene-1-yl] amino }-quinazoline
The fluoro-phenyl of the chloro-4-of 4-[(3-) amino]-6-[2-(2,2-dimethyl-6-oxo-morpholine-4-yl)-ethyoxyl]-7-methoxyl group-quinazoline
The fluoro-phenyl of the chloro-4-of 4-[(3-) amino]-6-[2-(2,2-dimethyl-6-oxo-morpholine-4-yl)-ethyoxyl]-7-[(R)-(oxolane-2-yl) methoxyl group]-quinazoline
The fluoro-phenyl of the chloro-4-of 4-[(3-) amino]-7-[2-(2,2-dimethyl-6-oxo-morpholine-4-yl)-ethyoxyl]-6-[(S)-(oxolane-2-yl) methoxyl group]-quinazoline
The fluoro-phenyl of the chloro-4-of 4-[(3-) amino]-6-{2-[4-(2-oxo-morpholine-4-yl)-piperidin-1-yl]-ethyoxyl }-7-methoxyl group-quinazoline
The fluoro-phenyl of the chloro-4-of 4-[(3-) amino]-6-[1-(tert-butyl group oxygen base carbonyl)-piperidin-4-yl oxygen base]-7-methoxyl group-quinazoline
The fluoro-phenyl of the chloro-4-of 4-[(3-) amino]-6-(trans-4-amino-hexamethylene-1-base oxygen base)-7-methoxyl group-quinazoline
The fluoro-phenyl of the chloro-4-of 4-[(3-) amino]-6-(trans-4-methane sulfonyl amino-hexamethylene-1-base oxygen base)-7-methoxyl group-quinazoline
The fluoro-phenyl of the chloro-4-of 4-[(3-) amino]-6-(tetrahydropyran-3-base oxygen base)-7-methoxyl group-quinazoline
The fluoro-phenyl of the chloro-4-of 4-[(3-) amino]-6-(1-methyl-piperidin-4-yl oxygen base)-7-methoxyl group-quinazoline
The fluoro-phenyl of the chloro-4-of 4-[(3-) amino]-6-{1-[(morpholine-4-yl) carbonyl]-piperidin-4-yl oxygen base }-7-methoxyl group-quinazoline
The fluoro-phenyl of the chloro-4-of 4-[(3-) amino]-the 6-{1-[(methoxy) carbonyl]-piperidin-4-yl oxygen base }-7-methoxyl group-quinazoline
The fluoro-phenyl of the chloro-4-of 4-[(3-) amino]-6-(piperidines-3-base oxygen base)-7-methoxyl group-quinazoline
The fluoro-phenyl of the chloro-4-of 4-[(3-) amino]-6-[1-(2-acetyl-amino-ethyl)-piperidin-4-yl oxygen base)-7-methoxyl group-quinazoline
The fluoro-phenyl of the chloro-4-of 4-[(3-) amino]-6-(tetrahydropyran-4-base oxygen base)-7-ethyoxyl-quinazoline
The fluoro-phenyl of the chloro-4-of 4-[(3-) amino]-6-((S)-oxolane-3-base oxygen base)-7-hydroxyl-quinazoline
The fluoro-phenyl of the chloro-4-of 4-[(3-) amino]-6-(tetrahydropyran-4-base oxygen base)-7-(2-methoxyl group-ethyoxyl)-quinazoline
The fluoro-phenyl of the chloro-4-of 4-[(3-) amino]-the trans-4-[(dimethylamino of 6-{) sulfuryl amino]-hexamethylene-1-base oxygen base }-7-methoxyl group-quinazoline
The fluoro-phenyl of the chloro-4-of 4-[(3-) amino]-the trans-4-[(morpholine of 6-{-4-yl) carbonylamino]-hexamethylene-1-base oxygen base }-7-methoxyl group-quinazoline
The fluoro-phenyl of the chloro-4-of 4-[(3-) amino]-the trans-4-[(morpholine of 6-{-4-yl) sulfuryl amino]-hexamethylene-1-base oxygen base }-7-methoxyl group-quinazoline
The fluoro-phenyl of the chloro-4-of 4-[(3-) amino]-6-(tetrahydropyran-4-base oxygen base)-7-(2-acetyl-amino-ethyoxyl)-quinazoline
The fluoro-phenyl of the chloro-4-of 4-[(3-) amino]-6-(tetrahydropyran-4-base oxygen base)-7-(2-methane sulfonyl amino-ethyoxyl)-quinazoline
The fluoro-phenyl of the chloro-4-of 4-[(3-) amino]-the 6-{1-[(piperidin-1-yl) carbonyl]-piperidin-4-yl oxygen base }-7-methoxyl group-quinazoline
The fluoro-phenyl of the chloro-4-of 4-[(3-) amino]-6-(1-amino carbonyl methyl-piperidin-4-yl oxygen base)-7-methoxyl group-quinazoline
The fluoro-phenyl of the chloro-4-of 4-[(3-) amino]-6-(cis-4-{N-[(tetrahydropyran-4-base) carbonyl]-N-methyl-amino }-hexamethylene-1-base oxygen base)-7-methoxyl group-quinazoline
The fluoro-phenyl of the chloro-4-of 4-[(3-) amino]-6-(cis-4-{N-[(morpholine-4-yl) carbonyl]-N-methyl-amino }-hexamethylene-1-base oxygen base)-7-methoxyl group-quinazoline
The fluoro-phenyl of the chloro-4-of 4-[(3-) amino]-6-(cis-4-{N-[(morpholine-4-yl) sulfonyl]-N-methyl-amino }-hexamethylene-1-base oxygen base)-7-methoxyl group-quinazoline
The fluoro-phenyl of the chloro-4-of 4-[(3-) amino]-6-(trans-4-ethane sulfuryl amino-hexamethylene-1-base oxygen base)-7-methoxyl group-quinazoline
The fluoro-phenyl of the chloro-4-of 4-[(3-) amino]-6-(1-methane sulfonyl-piperidin-4-yl oxygen base)-7-ethyoxyl-quinazoline
The fluoro-phenyl of the chloro-4-of 4-[(3-) amino]-6-(1-methane sulfonyl-piperidin-4-yl oxygen base)-7-(2-methoxyl group-ethyoxyl)-quinazoline
The fluoro-phenyl of the chloro-4-of 4-[(3-) amino]-6-[1-(2-methoxyl group-acetyl group)-piperidin-4-yl oxygen base]-7-(2-methoxyl group-ethyoxyl)-quinazoline
The fluoro-phenyl of the chloro-4-of 4-[(3-) amino]-6-(cis-4-acetyl-amino-hexamethylene-1-base oxygen base)-7-methoxyl group-quinazoline
4-[(3-acetenyl-phenyl) amino]-6-[1-(tert-butyl group oxygen base carbonyl)-piperidin-4-yl oxygen base]-7-methoxyl group-quinazoline
4-[(3-acetenyl-phenyl) amino]-6-(tetrahydropyran-4-base oxygen base]-7-methoxyl group-quinazoline
The fluoro-phenyl of the chloro-4-of 4-[(3-) amino]-6-(cis-4-{N-[(piperidin-1-yl) carbonyl]-N-methyl-amino }-hexamethylene-1-base oxygen base)-7-methoxyl group-quinazoline
The fluoro-phenyl of the chloro-4-of 4-[(3-) amino]-6-(cis-4-{N-[(4-methyl-piperazine-1-yl) carbonyl]-N-methyl-amino }-hexamethylene-1-base oxygen base)-7-methoxyl group-quinazoline
The fluoro-phenyl of the chloro-4-of 4-[(3-) amino]-the cis-4-[(morpholine of 6-{-4-yl) carbonylamino]-hexamethylene-1-base oxygen base }-7-methoxyl group-quinazoline
The fluoro-phenyl of the chloro-4-of 4-[(3-) amino]-6-{1-[2-(2-oxo-pyrrolidine-1-yl) ethyl]-piperidin-4-yl oxygen base }-7-methoxyl group-quinazoline
The fluoro-phenyl of the chloro-4-of 4-[(3-) amino]-6-{1-[(morpholine-4-yl) carbonyl]-piperidin-4-yl oxygen base }-7-(2-methoxyl group-ethyoxyl)-quinazoline
4-[(3-acetenyl-phenyl) amino]-6-(1-acetyl group-piperidin-4-yl oxygen base)-7-methoxyl group-quinazoline
4-[(3-acetenyl-phenyl) amino]-6-(1-methyl-piperidin-4-yl oxygen base)-7-methoxyl group-quinazoline
4-[(3-acetenyl-phenyl) amino]-6-(1-methane sulfonyl-piperidin-4-yl oxygen base)-7-methoxyl group-quinazoline
The fluoro-phenyl of the chloro-4-of 4-[(3-) amino]-6-(1-methyl-piperidin-4-yl oxygen base)-7-(2-methoxyl group-ethyoxyl) quinazoline
The fluoro-phenyl of the chloro-4-of 4-[(3-) amino]-6-(1-isopropyl oxygen base carbonyl-piperidin-4-yl oxygen base)-7-methoxyl group-quinazoline
The fluoro-phenyl of the chloro-4-of 4-[(3-) amino]-6-(cis-4-methylamino-hexamethylene-1-base oxygen base)-7-methoxyl group-quinazoline
The fluoro-phenyl of the chloro-4-of 4-[(3-) amino]-the cis-4-[N-of 6-{ (2-methoxyl group-acetyl group)-N-methyl-amino]-hexamethylene-1-base oxygen base }-7-methoxyl group-quinazoline
4-[(3-acetenyl-phenyl) amino]-6-(piperidin-4-yl oxygen base)-7-methoxyl group-quinazoline
4-[(3-acetenyl-phenyl) amino]-6-[1-(2-methoxyl group-acetyl group)-piperidin-4-yl oxygen base]-7-methoxyl group-quinazoline
4-[(3-acetenyl-phenyl) amino]-6-{1-[(morpholine-4-yl) carbonyl]-piperidin-4-yl oxygen base }-7-methoxyl group-quinazoline
The fluoro-phenyl of the chloro-4-of 4-[(3-) amino]-6-{1-[(is cis-2,6-dimethyl-morpholine-4-yl) carbonyl]-piperidin-4-yl oxygen base]-7-methoxyl group-quinazoline
The fluoro-phenyl of the chloro-4-of 4-[(3-) amino]-6-{1-[(2-methyl-morpholine-4-yl) carbonyl]-piperidin-4-yl oxygen base]-7-methoxyl group-quinazoline
The fluoro-phenyl of the chloro-4-of 4-[(3-) amino]-6-{1-[(S, S)-(2-oxa--5-aza-bicyclo [2.2.1] heptan-5-yl) carbonyl]-piperidin-4-yl oxygen base]-7-methoxyl group-quinazoline
The fluoro-phenyl of the chloro-4-of 4-[(3-) amino]-6-{1-[(N-methyl-N-2-methoxy ethyl-amino) carbonyl]-piperidin-4-yl oxygen base }-7-methoxyl group-quinazoline
The fluoro-phenyl of the chloro-4-of 4-[(3-) amino]-6-(1-ethyl-piperidin-4-yl oxygen base)-7-methoxyl group-quinazoline
The fluoro-phenyl of the chloro-4-of 4-[(3-) amino]-the 6-{1-[(2-methoxy ethyl) carbonyl]-piperidin-4-yl oxygen base }-7-methoxyl group-quinazoline
The fluoro-phenyl of the chloro-4-of 4-[(3-) amino]-6-{1-[(3-methoxy-propyl-amino) carbonyl]-piperidin-4-yl oxygen base }-7-methoxyl group-quinazoline
The fluoro-phenyl of the chloro-4-of 4-[(3-) amino]-the cis-4-of 6-[(N-methane sulfonyl-N-methyl-amino)-hexamethylene-1-base oxygen base]-7-methoxyl group-quinazoline
The fluoro-phenyl of the chloro-4-of 4-[(3-) amino]-the cis-4-of 6-[(N-acetyl group-N-methyl-amino)-hexamethylene-1-base oxygen base]-7-methoxyl group-quinazoline
The fluoro-phenyl of the chloro-4-of 4-[(3-) amino]-6-(trans-4-methylamino-hexamethylene-1-base oxygen base)-7-methoxyl group-quinazoline
The fluoro-phenyl of the chloro-4-of 4-[(3-) amino]-the trans-4-of 6-[(N-methane sulfonyl-N-methyl-amino)-hexamethylene-1-base oxygen base]-7-methoxyl group-quinazoline
The fluoro-phenyl of the chloro-4-of 4-[(3-) amino]-6-(trans-4-dimethylamino-hexamethylene-1-base oxygen base)-7-methoxyl group-quinazoline
The fluoro-phenyl of the chloro-4-of 4-[(3-) amino]-6-(trans-4-{N-[(morpholine-4-yl) carbonyl]-N-methyl-amino }-hexamethylene-1-base oxygen base)-7-methoxyl group-quinazoline
The fluoro-phenyl of the chloro-4-of 4-[(3-) amino]-6-[2-(2,2-dimethyl-6-oxo-morpholine-4-yl)-ethyoxyl]-7-[(S)-(oxolane-2-yl) methoxyl group]-quinazoline
The fluoro-phenyl of the chloro-4-of 4-[(3-) amino]-6-(1-methane sulfonyl-piperidin-4-yl oxygen base)-7-methoxyl group-quinazoline
The fluoro-phenyl of the chloro-4-of 4-[(3-) amino]-6-(1-cyano group-piperidin-4-yl oxygen base)-7-methoxyl group-quinazoline,
Optional with the form of its racemic modification, enantiomer or diastereomer and optionally with the acceptable acid-addition salts of its pharmacology, solvate or hydrate forms.According to the present invention, these acid-addition salts preferably are selected from following each salt: hydrochlorate, hydrobromate, hydriodate, sulfate, phosphate, nitrate, maleate, acetate, citrate, fumarate, tartrate, oxalates, succinate, benzoate and tosilate.
The dopamine agonist used preferably is selected from the compound in following material: bromocriptine, cabergoline, α-dihydro ergocryptine (α-Dihydroergocryptine), lisuride, pergolide, pramipexole, Roxindole, ropinirole, talipexole, terguride and dimension are praised (Viozane), it optionally is racemic form, for enantiomer, diastereomer, or be optionally pharmacology upper acceptable salt, solvate or hydrate.According to the present invention, these acid-addition salts are preferably and are selected from following each salt: hydrochlorate, hydrobromate, hydriodate, sulfate, phosphate, methane sulfonates, nitrate, maleate, acetate, citrate, fumarate, tartrate, oxalates, succinate, benzoate and tosilate.
Spendable H1-antihistaminic preferably is selected from the compound in following material: epinastine, cetirizine, azelastine, fexofenadine, levocabastine, loratadine, mizolastine, can be how for fragrant (Ketotifen), emedastine, dimetindene, clemastine, bamipine, dexchlorpheniramine (Cexchlorpheniramine), pheniramine, doxylamine, chlorphenoxamine, dimenhydrinate, diphenhydramine, promethazine, ebastine, ground Loratadine (Desloratidine) and meclizine, it optionally is racemic form, as enantiomer, diastereomer, or be optionally the upper acceptable salt of pharmacology, solvate or hydrate.According to the present invention, these acid-addition salts are preferably freely following each salt of choosing: hydrochlorate, hydrobromate, hydriodate, sulfate, phosphate, nitrate, maleate, acetate, citrate, fumarate, tartrate, oxalates, succinate, benzoate and tosilate.
Also can use as EP1 003,478A1 or CA2, the disclosed macromole that sucks in 297,174A1.
In addition, described compound can be selected from the derivant of following each material: the derivant of peptide, triptan (triptane), CGRP-antagonist, phosphodiesterase-V-inhibitor, it optionally is racemic modification, enantiomer, diastereomeric form, and optional its pharmacology upper acceptable acid-addition salts, solvate and/or hydrate.
The example of peptide derivant is dihydroergotamine and Ergotamine.
Claims (26)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102006023657.2 | 2006-05-18 | ||
DE102006023657 | 2006-05-18 | ||
DE102006043637A DE102006043637A1 (en) | 2006-05-18 | 2006-09-18 | atomizer |
DE102006043637.7 | 2006-09-18 | ||
PCT/EP2007/004418 WO2007134794A1 (en) | 2006-05-18 | 2007-05-16 | Atomiser |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101437563A CN101437563A (en) | 2009-05-20 |
CN101437563B true CN101437563B (en) | 2013-06-26 |
Family
ID=40711566
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200780016624.0A Active CN101437563B (en) | 2006-05-18 | 2007-05-16 | atomizer |
CNA2007800170195A Pending CN101443065A (en) | 2006-05-18 | 2007-05-16 | Atomiser |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNA2007800170195A Pending CN101443065A (en) | 2006-05-18 | 2007-05-16 | Atomiser |
Country Status (1)
Country | Link |
---|---|
CN (2) | CN101437563B (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105013054B (en) * | 2015-07-30 | 2018-11-09 | 中山市美捷时包装制品有限公司 | A kind of more capsule dry-powder inhaling devices |
CN110201279B (en) * | 2018-02-28 | 2021-05-11 | 张江 | Medicine box for inhalation administration and inhalation administration combined structure |
CN112336959B (en) * | 2020-11-06 | 2022-06-10 | 昆山全泰信息科技服务有限公司 | Atomizer is made to clinical intelligence of portable anesthesia |
CN113877737B (en) * | 2021-12-08 | 2022-04-08 | 昌乐县人民医院 | Multifunctional injection device |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5533502A (en) * | 1993-05-28 | 1996-07-09 | Vortran Medical Technology, Inc. | Powder inhaler with aerosolization occurring within each individual powder receptacle |
-
2007
- 2007-05-16 CN CN200780016624.0A patent/CN101437563B/en active Active
- 2007-05-16 CN CNA2007800170195A patent/CN101443065A/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5533502A (en) * | 1993-05-28 | 1996-07-09 | Vortran Medical Technology, Inc. | Powder inhaler with aerosolization occurring within each individual powder receptacle |
Also Published As
Publication number | Publication date |
---|---|
CN101437563A (en) | 2009-05-20 |
CN101443065A (en) | 2009-05-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2426100T3 (en) | Atomizer | |
JP6056110B2 (en) | Inhaler | |
KR20080042085A (en) | sprayer | |
KR20120098404A (en) | Inhaler | |
CN101437563B (en) | atomizer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant |